10-K

United States Securities and Exchange Commission

Washington, D.C.  20549

Form 10-K

 ☒ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934:

For the fiscal year ending August 31, 2018

 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the transition period from ___________ to ___________.

Commission file number: 333-154989

ENTEST GROUP, INC.

(Name of small business issuer in its charter)

Nevada	26-3431263
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

4700 Spring Street, Suite 304, La Mesa, California, 91942

(Address of Principal executive offices)

Issuer’s telephone number: ( 619) 702-1404 

_______________

Securities registered under Section 12(b) of the “Exchange Act” None

Securities registered under Section 12(g) of the Exchange Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    

Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or smaller reporting company.

Large accelerated filer ☐	Accelerated filer ☐
Non accelerated filer ☐	Smaller reporting Company ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  

Yes ☒  No ☐ 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   

Yes  ☐ No☐ 

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, as of the last business day of the registrant’s most recently completed second fiscal quarter: $ 470,842

As of November 16, 2018 Entest BioMedical, Inc. had 49,170,472 common shares outstanding, 728, 009 Series B Preferred shares outstanding , 667 Series AA preferred shares outstanding , 534 Series AAA preferred shares outstanding and 1001533 shares outstanding of the Company’s Non Voting Convertible Preferred Stock. .

1

In this annual report, the terms “Entest BioMedical, Inc.. ”, “Entest”,  “Company”, “we”, or “our”, unless the context otherwise requires, mean Entest BioMedical, Inc., a Nevada corporation, and its subsidiaries.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This annual report on Form 10-K and other reports that we file with the SEC contain statements that are considered forward-looking statements.  Forward-looking statements give the Company’s current expectations, plans, objectives, assumptions or forecasts of future events. All statements other than statements of current or historical fact contained in this annual report, including statements regarding the Company’s future financial position, business strategy, budgets, projected costs and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “estimate,” “plans,” “potential,” “projects,” “ongoing,” “expects,” “management believes,” “we believe,” “we intend,” and similar expressions. These statements are based on the Company’s current plans and are subject to risks and uncertainties, and as such the Company’s actual future activities and results of operations may be materially different from those set forth in the forward looking statements. Any or all of the forward-looking statements in this annual report may turn out to be inaccurate and as such, you should not place undue reliance on these forward-looking statements.  The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. The forward-looking statements can be affected by inaccurate assumptions or by known or unknown risks, uncertainties and assumptions due to a number of factors.

These forward-looking statements speak only as of the date on which they are made, and except to the extent required by federal securities laws, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements contained in this annual report.

PART I

Item 1. Business

We were incorporated in the State of Nevada on September 24, 2008 as JB Clothing Corporation. Until July 10, 2009, our principal business objective was the offering of active/leisure fashion design clothing.

On July 10, 2009 we abandoned our efforts in the field of active/leisure fashion design clothing when we acquired 100% of the share capital of Entest BioMedical, Inc., a California corporation, (“Entest CA”) from Bio-Matrix Scientific Group, Inc. (“BMSN”) for consideration consisting of 10,000,000 shares of the common stock of the Company and the cancellation of 10,000,000 shares of the Company owned and held by Mr. Rick Plote.

As a result of this transaction, the former stockholder of Entest CA held approximately 70% of the voting capital stock of the Company immediately after the transaction. For financial accounting purposes, this acquisition was a reverse acquisition of the Company by Entest CA under the purchase method of accounting, and was treated as a recapitalization with Entest CA as the acquirer..

Upon acquisition of Entest CA, we abandoned our efforts in the field of active/leisure fashion design clothing. On July 12, 2009 we adopted the name of Entest CA when we changed our name to Entest BioMedical, Inc. On June 18, 2015 Entest established Zander Therapeutics, Inc., a then wholly owned subsidiary. Zander was established to engage primarily in the development and commercialization of veterinary medical therapies which we intend to license from other entities as well as develop internally

2

The Company changed its name to Entest Group, Inc. on February 12, 2018.

On May 5, 2018, The Company declared the distribution on a pro rata basis as a dividend in kind of 3,000,000 of the common shares of Zander Therapeutics, Inc., par value $0.0001, currently owned by Entest Group, Inc. to:

(a) Holders of record of the outstanding common shares of the Company as of the record date, which is May 30, 2018.

(b) Holders of record of the shares of any outstanding series of the preferred shares of the Company as of the record date, which is May 30, 2018.

Shareholders of the Company shall receive one (1) common share of Zander Therapeutics, Inc. for each 17 common and/or preferred shares of the Company held as of the record date. The distribution of the 3,000,000 common shares of Zander Therapeutics, Inc. to the common and preferred shareholders of the Company occurred on June 11, 2018 ("Distribution Date").

As a result of the payment of the abovementioned property dividend, the Company’s percentage of ownership of Zander fell below 50% resulting in the deconsolidation of Zander as of the Distribution Date. As of the Distribution Date all assets and liabilities attributable to Zander were derecognized by the Company. The Company recognized a $10,034 gain as a result of the deconsolidation. The Property dividend may be deemed to have occurred with a related party as the recipients were shareholders of Entest, including the Chairman and Chief Executive Officer of Entest and Regen Biopharma, Inc. which is a company under common control with Entest.

The Company’s remaining share of Zander , which consists of 5,000,000 shares of Zander’s Series M Preferred Stock (“Zander M Stock”) is accounted for under the Equity Method as of the Distribution Date. The Zander M Stock is carried a Fair Value and the carrying value is increased by the Company’s proportionate share of earnings of Zander and decreased by cash dividends paid by Zander as well as the Company’s proportionate share of losses of Zander up to the carrying value . As of August 31, 2018 the carrying value of the Zander M Stock has been decreased by the Company’s proportionate share of the losses of Zander and is 0. As of August 31, 2018 Entest beneficially owns 34.82% of the share equity of Zander.

As of November 16, 2018 the Company is a “shell company” as that term is defined in Rule 12b-2 of the Securities and Exchange Act which is a registrant that has:

(1) No or nominal operations; and

(2) Either:

(i) No or nominal assets;

(ii) Assets consisting solely of cash and cash equivalents; or

(iii) Assets consisting of any amount of cash and cash equivalents and nominal other assets.

The Company's current business strategy is to acquire an operating company seeking the perceived advantages of being a publicly held corporation. No assurance can be given that such an acquisition shall occur or, if such an acquisition were to occur, it would occur on terms and conditions beneficial to the Company or its shareholders.

Distribution methods of the products or services:

Entest currently provides no product or service

3

Competitive business conditions and Entest's competitive position in the industry and methods of competition

The Company will face vast competition from other shell companies that desire to seek a potential business combination with a private company seeking the perceived advantages of being a publicly held corporation. The Company will be in a highly competitive market for a small number of business opportunities which could reduce the likelihood of consummating a successful business combination. A large number of established and well-financed entities, including small public companies and venture capital firms, are active in mergers and acquisitions of companies that may be desirable target candidates for us. Nearly all these entities have significantly greater financial resources, technical expertise and managerial capabilities than we do; consequently, we will be at a competitive disadvantage in identifying possible business opportunities and successfully completing a business combination. These competitive factors may reduce the likelihood of our identifying and consummating a successful business

combination.

Need for any government approval of principal products or services, effect of existing or probable governmental regulations on the business

The Company is unaware of any government approval currently required in order for the Company to complete an acquisition of an operating company. The Company is subject to federal and state securities laws.

Amount spent during the last fiscal year on research and development activities

During the fiscal year ended August 31, 2018 the consolidated Company expended $949,584 on research and development activities.

Costs and effects of compliance with environmental laws (federal, state and local);

Entest has not incurred any unusual or significant costs to remain in compliance with any environmental laws and does not expect to incur any unusual or significant costs to remain in compliance with any environmental laws in the foreseeable future.

Number of total employees and number of full-time employees

As of November 16, 2018, the Company has 1 employee of which 1 is partl time.

Sources and availability of raw materials and the names of principal suppliers

Entest currently has no need for raw materials or supplies

Patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts, including duration.

Entest possesses no patents or trademarks. Entest has not been granted any license, franchise or concession. Entest is not party to any royalty agreement or labor contract.

Item 2. Properties

On November 1, 2011, the Company entered into an agreement to lease approximately 2,320 square feet of office space beginning December 1, 2011 for a period of five years.

Rent to be charged to the Company pursuant to the lease is as follows:

$2,996 per month for the period beginning December 1, 2011 and ending November 30, 2012

$3,116 per month for the period beginning December 1, 2012 and ending November 30, 2013

$3,241 per month for the period beginning December 1, 2013 and ending November 30, 2014

$3,371 per month for the period beginning December 1, 2014 and ending November 30, 2015

$3,506 per month for the period beginning December 1, 2015 and ending November 30, 2016

4

On November 27, 2016 the lease was extended until November 30, 2021

Rent to be charged to the Company pursuant to the extension is as follows:

$2,996 per month for the period beginning December 1, 2016 and ending November 30, 2017

$3,116 per month for the period beginning December 1, 2017 and ending November 30, 2018

$3,241 per month for the period beginning December 1, 2018 and ending November 30, 2019

$3,371 per month for the period beginning December 1, 2019 and ending November 30, 2020

$3,506 per month for the period beginning December 1, 2020 and ending November 30, 2021

This property is utilized as office space. The Company believes that the foregoing property is adequate to meet its current needs.

Item 3. Legal Proceedings

None

Item 4. Submission of Matters to a Vote of Security Holders

No matter was submitted during the fourth quarter of the fiscal year covered by this report to a vote of security holders, through the solicitation of proxies or otherwise.

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

The Company’s common stock is a "penny stock," as defined in Rule 3a51-1 under the Exchange Act. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its sales person in the transaction, and monthly account statements showing the market value of each penny stock held in the customer's account. In addition, the penny stock rules require that the broker-dealer, not otherwise exempt from such rules, must make a special written determination that the penny stock is suitable for the purchaser and receive the purchaser's written agreement to the transaction. These disclosure rules have the effect of reducing the level of trading activity in the secondary market for a stock that becomes subject to the penny stock rules. So long as the common stock of the Company is subject to the penny stock rules, it may be more difficult to sell common stock of the Company.

The Company’s authorized capital stock consists of 500,000,000 shares of common stock with a par value $0.0001, and 5,000,000 shares of preferred stock with a par value $0.0001 per share (of which 100,000 are designated as Series AA Preferred Stock, 4,400,000 are designated as Series B Preferred Stock and 300,000 are designated as Series AAA Preferred Stock) and 3,000,000 shares authorized of Non Voting Convertible Preferred Stock, par value $1.00 . As of November 16,2018 Entest BioMedical, Inc. had 49,170,472 common shares outstanding, 728, 009 Series B Preferred shares outstanding , 667 Series AA preferred shares outstanding, 534 Series AAA preferred shares outstanding, and 1001533 shares of the Company’s Non Voting Convertible Preferred Stock outstanding.

(a) Our common stock is traded on the OTC Pink Tier of OTC Markets under the symbol "ETNI”. Below is the range of high and low price information for our common equity for each quarter within the last two fiscal years as reported by OTC Markets.

5

September 1, 2017 to August 31, 2018	High		Low
First Quarter	$	0.0182	$	0.0068
Second Quarter		0.0205		0.0068
Third Quarter		0.0405		0.0092
Fourth Quarter	$	0.054	$	0.011
September 1, 2016 to August 31, 2017		High		Low
First Quarter	$	0.0919	$	0.0038
Second Quarter		0.0559		0.02
Third Quarter		0.055		0.015
Fourth Quarter	$	0.0201	$	0.045

Holders

As of August 31, 2018 there were approximately 40 holders of our Common Stock.

Dividends

No cash dividends were paid during the fiscal year ending August 31, 2018. We do not expect to declare cash dividends in the immediate future.

Recent Sales of Unregistered Securities

On September 8, 2017 the Company issued 2,500,000 Common Shares (“Shares”)in connection with a conversion of 25,000 Non Voting Convertible Preferred Shares.

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares. A legend was placed on the certificate that evidences the Shares stating that the Shares have not been registered under the Act and setting forth or referring to the restrictions on transferability and sale of the Shares.

Item 6. Selected Financial Data

As we are a “smaller reporting company” as defined by Rule 229.10(f)(1), we are not required to provide the information required by this Item.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 

As of August 31, 2017, we had Cash in the amount of $86,559 and as of August 31, 2018 we had Cash in the amount of $267.

The decrease in Cash of approximately 99.7% is primarily attributable to the derecognition of the assets of Zander Therapeutics, Inc. which was deconsolidated from the Company on June 11, 2018.

As of August 31, 2017 we had Accrued Interest Receivable of $908 and as of August 31 2018 we had Accrued Interest Receivable of $1,040.

The increase in Accrued Interest Receivable of approximately 14.2% is attributable to $132 of interest earned by the Company during the quarter ended February 28, 2018 resulting from a short term loan made by the Company, the principal on such loan paid during the quarter ended February 28, 2018.

As of August 31, 2017 we had Prepaid Expenses of $58,652 and as of the end of the same period ended 2018 we had Prepaid Expenses of $8,000.

The decrease in Prepaid Expenses of approximately 86.3% is primarily attributable to $50,652 of fees prepaid to consultants during the fiscal year ended 2017.

6

As of August 31, 2017 we had Securities Available for Sale in the amount of $190,050 and as of August 31, 2018 we had Securities Available for Sale in the amount of $0.

The decrease in Securities Available for Sale is attributable to the sale by the Company of 3,500,000 of the Series A Preferred shares of Regen Biopharma, Inc.to Zander Therapeutics, Inc.

David R. Koos, the Chairman and Chief Executive Officer of the Company, serves in the same capacity at Regen Biopharma, Inc. and Zander Therapeutics, Inc.

As of August 31, 2017 we had Notes Payable of $13,501 and as of August 31, 2018 we had Notes Payable of $19,601.

The increase in Notes Payable of approximately 45.1% is attributable to the incurrence of an additional $2,500 of principal indebtedness from the Company’s Chairman and incurrence of an additional $3,600 of principal indebtedness from an entity controlled by the Company’s Chairman.

As of August 31, 2017 we had Accrued Expenses of $269,398 and as of August 31, 2018 we had Accrued Expenses of $181,904.

The reduction in accrued expenses of approximately 32.4% is primarily attributable to payment during the year ended August 31, 2018 of $88,000 of salary accrued but unpaid to David R. Koos, the Company’s sole officer as well as derecognition of $818 of accrued interest during the year ended August 31 2018 attributable to the deconsolidation of Zander Therapeutics, Inc. offset by interest accrued but unpaid due on Notes payable.

As of August 31, 2018 we had Unearned Rental Income of $17,000 and as of August 31, 2017 we had Unearned Rental Income of $0.

The increase in Unearned Rental Income is attributable to rental income prepaid to the Company by Regen Biopharma, Inc. Regen Biopharma, Inc. is under common control with the Company.

As of August 31, 2018 we had a bank overdraft of $66 and as of August 31, 2017 we had a bank overdraft of $0.

The increase in bank overdraft is attributable to withdrawals of $66 in excess of the balance of a bank account maintained by the Company.

Revenues from continuing operations were $0 for the year ended August 31, 2017 and -0- for the year ended August 31, 2018. Net Losses from continuing operations were $664,792 for the year ended August 31, 2017 and $1,477,484 for the same period ended 2018.

The increase in Net Loss of approximately 122.2% is primarily attributable to Research and Development Fees incurred by Zander Therapeutics, Inc. during that period of the fiscal year during which Zander Therapeutics, Inc. was a consolidated subsidiary of the Company and recognition of the Company’s equity in the losses of Zander Therapeutics, Inc. during the period beginning June 11, 2018 and ending August 31, 2018. These losses were offset by gains on sale of investment securities and a one time gain of $10,034 recognized in connection with the deconsolidation of Zander Therapeutics, Inc.

7

As of August 31, 2018 we had $267 cash on hand and current liabilities of $255,018 such liabilities consisting of Accounts Payable, Notes Payable, Amounts due to Others and Accrued Expenses.

We feel we will not be able to satisfy our cash requirements over the next twelve months. The Company seeks to acquire an operating company seeking the perceived advantages of being a publicly held corporation. No assurance can be given that such an acquisition shall occur or, if such an acquisition were to occur, it would occur on terms and conditions beneficial to the Company or its shareholders.

As of November 16, 2018 we are not party to any binding agreements which would commit Entest to any material capital expenditures.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

As we are a smaller reporting company, as defined by Rule 229.10(f)(1), we are not required to provide the information required by this Item.

8

Item 8. Financial Statements and Supplementary Data

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 

To the Board of Directors and Stockholders of

Entest Group, Inc. (FKA Entest Biomedical, Inc.)

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Entest Group, Inc. (the “Company”) as of August 31, 2018 and August 31, 2017 and the related statements of operations, comprehensive income, stockholders’ equity, and cash flows for each of the years in the two-year period ended August 31, 2018, and the related notes and schedules (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of August 31, 2018 and August 31, 2017, and the results of its operations and its cash flows for each of the years in the two-year period ended August 31, 2018 in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 4 to the financial statements, the Company has no revenues, has negative working capital at August 31, 2018, has incurred recurring losses and recurring negative cash flow from operating activities, and has an accumulated deficit which raises substantial doubt about its ability to continue as a going concern. Management’s plans concerning these matters are also described in Note 4. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ AMC Auditing

AMC Auditing
We have served as the Company’s auditor since 2012

Las Vegas, Nevada

November 19, 2018

9

ENTEST GROUP,INC.
(Formerly called ENTEST BIOMEDICAL, INC.)
Consolidated Balance Sheet
	As of August 31, 2018		August 31, 2017
ASSETS
Current Assets
Cash	267		86,559
Accrued Interest Receivable	1,040		908
Current Portion of Prepaid Expenses	8,000		58,652
Accrued Rent Receivable	0		0
Total Current Assets	9,307		146,119
OTHER ASSETS
Available for Sale Securities	0		190,050
Long Term Portion Prepaid Expenses	0		0
TOTAL ASSETS	9,307		336,169
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts Payable	28,447		28,446
Notes Payable	19,601		13,501
Due to Other	8,000		8,000
Unearned Rental Income	17,000		0
Bank Overdraft	66		0
Accrued Expenses	181,904		269,398
Total Current Liabilities	255,018		319,345
TOTAL LIABILITIES	255,018		319,345
STOCKHOLDERS' EQUITY
Common Stock,  authorized 500,000,000  shares as of August 31, 2017 and August 31, 2018; issued and outstanding 46,670,472(par value $0.0001) as of August 31, 2017 and  49,170,472 as of August 31, 2018	4,911		4,661
Preferred Stock ,par value  $0.0001  5,000,000 shares authorized, Series AA Preferred Stock, 100,000 shares authorized, 667 shares, par value $0.0001, issued and outstanding at August 31, 2017 and as of August 31, 2018	0		0
Series B Preferred 4,400,000 shares authorized, 728,009 ( par value $0.0001) issued and outstanding  as of August 31, 2018 and 728,009 issued and outstanding as of  August 31, 2017	73		73
Series AAA Preferred, 300,000 shares authorized, $0.0001 par value 534 shares outstanding as of August 31, 2018 and as of August 31, 2017
NonVoting Convertible Preferred ($1 par value) 3,000,000 shares  authorized as of August 31, 2018 and August 31, 2017 respectively, 1,001,533 and 1,026,533 issued and outstanding as of August 31, 2018 and August 31, 2017, respectively	1,001,533		1,026,533
Additional Paid in Capital	8,729,236		7,191,000
Contributed Capital	274,662		274,662
Accumulated Deficit	(10,256,126	)	(8,721,498	)
Accumulated Other Comprehensive Income	0		185,050
Total Stockholders' Equity Entest Biomedical, Inc.	(245,711	)	(39,519	)
Non Controlling Interest Zander Therapeutics Inc.	0		56,343
Stockholders Equity	(245,711	)	16,824
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY	9,307		336,169
The accompanying Notes are an integral part of these Financial Statements

10

ENTEST GROUP,INC.
(Formerly called ENTEST BIOMEDICAL, INC.)
Consolidated Statement of Operations
	Year Ended		Year Ended
	August 31, 2018		August 31 2017
TOTAL REVENUE	0		0
COSTS AND EXPENSES
Research and Development	949,584		124,770
Rent Costs	37,032		37,482
General and Administrative	224,263		225,804
Consultant's Expenses	310,020		263,823
Total Costs and Expenses	1,520,899		651,879
OPERATING LOSS	(1,520,899	)	(651,879	)
OTHER INCOME AND EXPENSE
Rental income	66,000		60,000
Interest Income	132		1,056
Gain on Write Off of Accounts Payable			76,697
Loss on Issuance of Stock Below Fair Value			(107,700	)
Gain on Deconsolidation of Zander	10,034
Equity in Losses of Zander	(61,428	)
Gain on Sale of Securities	30,000
Interest Expense	(1,323	)	(42,966	)
TOTAL OTHER INCOME AND EXPENSE	43,415		(12,913	)
LOSS BEFORE INCOME TAXES	(1,477,484	)	(664,792	)
Income Taxes	0		0
NET LOSS
NET LOSS  from continuing	(1,477,484	)	(664,792	)
Operations
Less: (Net Income) Loss attributable to non controlling interest in Zander Therapeutics, Inc.			105,374
NET LOSS available to common shareholders	(1,477,484	)	(559,418	)
BASIC AND DILUTED EARNINGS (LOSS) PER SHARE FROM CONTINUING OPERATIONS	(0.030	)	(0.013	)
WEIGHTED AVERAGE NUMBER COMMON SHARES OUTSTANDING	48987813		42551431
The accompanying Notes are an integral part of these Financial Statements

11

ENTEST GROUP, INC.
(Formerly called ENTEST BIOMEDICAL, INC.)
Consolidated Statement of Comprehensive Income
		Year Ended August 31,			Year Ended August 31,
		2018			2017
Net Income (Loss)	$	(1477484	)	$	(664,792	)
Add:
Unrealized Gains on Securities		0			277,100
Less:
Unrealized Losses on Securities		0			(92,050	)
Comprehensive Income attributable to Non Controlling Interest		0			0
Total Other Comprehensive Income (Loss)		0			185,050
Comprehensive Income	$	(1477484	)	$	(479,742	)
The accompanying Notes are an integral part of these Financial Statements

12

	Common				Series AA Preferred				Series AAA Preferred				Series B Preferred				Non Voting Convertible Preferred
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares			Amount			Additional Paid-in Capital			Contributed Capital		Accumulated Other Comprehensive Income (Loss)			Accumulated Deficit during the Development Stage			Non Controlling interest In Subsidiary			Total
Balance August 31, 2016		40,170,472		4,011		667		0		533		0		28,009		3		0			0			6,148,054			274,162		0			(7,405,099	)		0			(978,869	)
Common Shares issued to Consultant January 27, 2017		100000		10																				4490														4,500
Common Shares issued for debt February 7, 2017		1000000		100																				9900														10,000
Common Shares issued for debt February 10, 2017		2,000,000		200																				19,800														20,000
Common Shares issued to Consultant March 10, 2017		100000		10																				4810														4,820
Series B Preferred shares issued to consultant  March 10, 2017														500000		50																						50
Series B Preferred shares issued to consultant  March 10, 2017														100000		10																						10
Series B Preferred shares issued to consultant  March 31, 2017														100000		10																						10
Common Stock Issued for Cash April 3, 2017		750000		75																				14,925														15,000
Common Stock of Subsidiary sold for Cash April 10, 2017																								20,000														20,000
Common Shares issued to Consultant May 30, 2017		100000		10																				3,390														3,400
Shares issued for Accrued Expenses May 30, 2017																		83000			83000																	83,000
Shares issued for Debt May 30, 2017																		840681			840681																	840,681
Beneficial Conversion Features recognized  May 30, 2017																								576,804														576,804
Amortization of Beneficial Conversion Feature May 30, 2017																																(576,804	)					(576,804	)
Preferred Shares of Subsidiary issued to consultants June 20, 2017																								100														100
Preferred Shares of Subsidiary issued to employees June 15, 2017																								150														150
Common Shares of Subsidiary issued for Cash July 10, 2017																								100,000														100,000
Common Shares of Subsidiary issued to Consultant 7/10/2017																								50														50
Preferred Shares of Subsidiary Issued to Consultants July 10, 2017																								10														10
Common Shares issued to Consultants July 24, 2017		2450000		245																				97,510														97,755
Shares issued for Accrued Expenses July 24, 2017																		102852			102852																	102,852
Beneficial Conversion Features recognized  July 24, 2017																								74,801														74,801
Amortization of Beneficial Conversion Feature July 24, 2017																																(74,801	)					(74,801	)
Preferred Shares of Subsidiary Issued to Consultants August 21, 2017																								140														140
Restricted Stock Expense Recognized During the Year Ended August 31, 2017																								64,709														64,709
Accumulated Other Comprehensive Income Recognized During the Year Ended
August 31, 2017																													185050									185,050
Loss on Issuance below Fair Value																								107,700														107,700
Net Loss for the Year Ended August 31, 2017																																(664,792	)					(664,792	)
Non Controlling Interest in Subsidiary																								(56,343	)										56343			0
Increase in Contributed Capital Year Ended 8/31/2017																											500											500
Balance August 31, 2017		46,670,472		4,661		667		0		533		0		728,009		73		1,026,533			1,026,533			7,191,000			274,662		185050			(8,721,498	)		56343			16,824
Common Shares issued for NonVoting Convertible Preferred Shares September 8, 2017		2,500,000		250														(25,000	)		(25,000	)		24,750														0
Common Shares of Subsidiary issued for Cash October 30, 2017																								900,000														900,000
Common Shares of Subsidiary issued for Cash February 5, 2018																								200,000														200,000
Common Shares of Subsidiary issued for Cash February 27, 2018																								300,000														300,000
Declaration of property Dividend May 5, 2018																																(57,143	)					(57,143	)
Payment of Property Dividend June 11, 2018																								57,143														57,143
Elimination of Noncontrolling Interest upon deconsolidation June 11, 2018																								56,343											(56,343	)		0
Sale of Securities of Securities Available for Sale																													(185,050	)								(185,050	)
Net Loss For Year Ended August 31, 2018																																(1,477,484	)					(1,477,484	)
Balalnce August 31, 2018		49,170,472		4,911		667		0		533		0		728,009		73		1,001,533			1,001,533			8,729,236			274,662		0			(10,256,126	)		0			(245,711	)
The accompanying Notes are an integral part of these Financial Statements

13

ENTEST GROUP,INC.
(Formerly called ENTEST BIOMEDICAL, INC.)
Consolidated Statement of Cash Flow
(unaudited)
	Year Ended		Year Ended
	August 31, 2018		August 31, 2017
OPERATING ACTIVITIES
Net (loss)	(1,477,484	)	(664,792	)
Adjustments to reconcile net loss to net cash used by operating activities:
Increase(Decrease) in stock of subsidiary issued to employees			150
Increase(Decrease) in stock of subsidiary issued to consultants			300
Increase (Decrease) in Additional paid in Capital	0		64,709
Increase ( Decrease) in Issuance of Stock below Faie Value	0		107,700
increase (Decrease) in Preferred Stock issued for expenses	0		185,852
Increase (Decrease) in Preferred Stock issued to Consultants			70
(Increase) Decrease in Gain attributable to Deconsolidation	(10,034	)
(Increase) Decrease Cash Lost in  Deconsolidation	(332,638	)
Equity in Losses of Zander	61,428
Increase (Decrease) Common Stock issued to Consultants			110,475
Changes in Operating Assets and Liabilities
(Increase) Decrease  in Prepaid Expenses	(117,388	)	(50,652	)
Increase(Decrease) in Unearned Rent	17,000
Increase (Decrease) in Accounts Payable	454,494		(83,716	)
(Increase) Decrease in Accrued Rental Income Receivable	0		15,000
Increase (Decrease) in Accrued Expenses	(85,347	)	(157,566	)
(Increase )Decrease in  Accrued Interest Receivable	(132	)	(909	)
(Increase) Decrease in Notes Receivable
Net Cash Provided (Used) in Operating Activities	(1,490,101	)	(473,380	)
Net Cash Provided ( Used) in Investing Activities:
Securities Purchased for Cash			(5,000	)
Gain on Sale of Securities received prior to deconsolidation	(2,357	)
Net Cash Provided ( Used) in Investing Activities:	(2,357	)	(5,000	)
FINANCING ACTIVITIES
Net Cash Provided (Used) in Financing Activities:
Common Stock issued for cash			15,000
Common Stock of Subsidiary issued for cash	1,400,000		120,000
Increase (Decrease) in Notes Payable	6,100		428,580
Increase(Decrease) Bank Overdraft	66
Increase (Decrease) in Contributed Capital			500
Net Cash Provided by Financing Activities	1,406,166		564,080
Net (Decrease) Increase in Cash	(86,292	)	85,700
Cash at Beginning of Period	86,559		859
Cash at End of Period	267		86,559
Supplemental Disclosure of Non CashInvesting and  Financing Activities:
Common Stock Issued for Debt			30,000
Preferred Stock issued for Debt			840,681
The accompanying Notes are an integral part  of these Financial Statements

14

The Entest Group,Inc.

(formerly known as Entest Biomedical, Inc.)

Notes to Consolidated Financial Statements

As of August 31, 2018

NOTE 1.  ORGANIZATION AND DESCRIPTION OF BUSINESS

Entest Biomedical, Inc ( The “Company”) was incorporated in the State of Nevada on September 24, 2008 as JB Clothing Corporation.  Until July 10, 2009, the Company’s principal business objective was the offering of active/leisure fashion design clothing.

On July 10, 2009 the Company abandoned its efforts in the field of active/leisure fashion design clothing when it acquired 100% of the share capital of Entest BioMedical, Inc., a California corporation, (“Entest CA”).

On June 18, 2015 the Company formed Zander Therapeutics, Inc. (“Zander”) , a Nevada corporation. As of August 31, 2018 Entest owns Zander 34.82% of Zander.

On February 12, 2018 the Company changed its name to The Entest Group, Inc.

As of August 31, 2018 the Company is a “Shell Company” as such term is defined in Rule 12(b)(2) promulgated under the Securities and Exchange Act of 1934 . This Rule defines as Shell Company as a company that has:

(1) No or nominal operations; and

(2) Either:

(i) No or nominal assets;

(ii) Assets consisting solely of cash and cash equivalents; or

(iii) Assets consisting of any amount of cash and cash equivalents and nominal other assets.

NOTE 2.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. BASIS OF ACCOUNTING

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted an August 31 fiscal year-end.   The Company recognizes revenue from services and product sales when the following four revenue recognition criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the selling price is fixed or determinable, and collectability is reasonably assured.

B. PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the accounts of Entest CA, the Company’s wholly owned subsidiary. These financial statement also include the accounts of Zander up to June 10, 2018. Significant inter-company transactions have been eliminated.

C. USE OF ESTIMATES

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

15

D. CASH EQUIVALENTS

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

E. PROPERTY AND EQUIPMENT

As of August 31, 2018 Property and Equipment consists of $0

F. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

Level 1:  Quoted prices in active markets for identical assets or liabilities

Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company’s financial instruments as of August 31, 2018 consisted of $ 19,601 of Notes Payable and $8,000 due to TheraCyte, Inc.. The fair value of all of the Company’s financial instruments as of August 31, 2018 were valued according to the Level 3 input. The carrying amount of the financial instruments is equal to the fair value as determined by the Company.

The Company has determined that there are no Level 1 or Level 2 inputs for determining the fair value of the Company’s financial instruments. Fair value was determined by the Company utilizing its own assumptions and estimation. There were no transfers between levels for the period presented.

G. INCOME TAXES

The Company accounts for income taxes using the liability method prescribed by ASC 740, “ Income Taxes. ” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company applied the provisions of ASC 740-10-50, “Accounting for Uncertainty in Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of August 31, 2018 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

16

The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

H.  BASIC EARNINGS (LOSS) PER SHARE

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. All convertible debt has an anti-dilutive effect on the EPS, therefore Diluted earnings per share are the same as basic earnings per share.

NOTE 3.  RECENT ACCOUNTING PRONOUNCEMENTS

In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as "Development Stage Entities" (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard.

The following accounting standards updates were recently issued and have not yet been adopted by the Company. These standards are currently under review to determine their impact on the Company’s consolidated financial position, results of operations, or cash flows.

In May 2014, FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. The revenue recognition standard affects all entities that have contracts with customers, except for certain items. The new revenue recognition standard eliminates the transaction-and industry-specific revenue recognition guidance under current GAAP and replaces it with a principle-based approach for determining revenue recognition. Public entities are required to adopt the revenue recognition standard for reporting periods beginning after December 15, 2016, and interim and annual reporting periods thereafter. Early adoption is not permitted for public entities. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.

In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award's grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.

17

In August2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure.

NOTE 4.  GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $10,256,126 during the period from August 22, 2008 (inception) through August 31, 2018. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Management intends to seek business opportunities to review and analyze for purposes of effecting a merger, acquisition or other business combination with an operating company business.

NOTE 5.  NOTES PAYABLE  

As of August 31, 2018

Notes Payable:

David Koos (See Note 6)	$	2,600
Dunhill Ross Partners, Inc.	$	850
Blackbriar Partners (See Note 6)		11,600
Regen Biopharma, Inc (See Note 6)		4,551
Total	$	19,601

$1,000 lent to the Company by Blackbriar Partners is due and payable February 17, 2018 and bears simple interest at a rate of 10% per annum

$7,000 lent to the Company by Blackbriar Partners is due and payable February 28, 2018 and bears simple interest at a rate of 10% per annum.

$3,000 lent to the Company by Blackbriar Partners is due and payable May 4, 2019 and bears simple interest at a rate of 10% per annum.

$600 lent to the Company by Blackbriar Partners is due and payable August 20, 2019 and bears simple interest at a rate of 10% per annum.

Blackbriar Partners is controlled by David R. Koos , the Company’s sole officer and director.

18

As of August 31, 2018 the Company remains indebted to David R. Koos , the Company’s sole officer and director, in the principal amount of $2,600 due and payable in whole or in part at the demand of David Koos and bearing simple interest at a rate of 15% per annum.

Amounts due to Regen Biopharma Inc. as of August 31, 2018 are due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum. David R. Koos , the Company’s sole officer, serves as Chairman and Chief Executive officer of Regen Biopharma, Inc.

NOTE 6.  RELATED PARTY TRANSACTIONS

As of August 31, 2018 the Company remains indebted to David R. Koos , the Company’s sole officer and director, in the principal amount of $2,600 due and payable in whole or in part at the demand of David Koos and bearing simple interest at a rate of 15% per annum.

As of August 31, 2018 the Company remains indebted to Blackbriar Partners in the principal amount of $11,600 of which $1,000 is  due and payable February 17, 2018 and bears simple interest at a rate of 10%per annum and of which $7,000 is due and payable February 28, 2018 and bears simple interest at a rate of 10% per annum , of which$3,000 is due and payable May 4, 2019 and bears simple interest at a rate of 10% per annum and of which $600 is due and payable August 20, 2019 and bears simple interest at a rate of 10% per annum.

Blackbriar Partners is controlled by David R. Koos , the Company’s sole officer and director.

As of August 31, 2018 the Company remains indebted to Regen Biopharma, Inc. in the principal amount of $4,551 due and payable in whole or in part at the demand of the holder and bearing simple interest at a rate of 10% per annum. David R. Koos , the Company’s sole officer, serves as Chairman and Chief Executive officer of Regen Biopharma, Inc.

 On October 1, 2014 Regen Biopharma Inc. entered into an agreement to sublease approximately 2,320 square feet of office space from the Company. Entest Biomedical Inc. is under common control with Regen Biopharma, Inc. as the Chairman and CEO of the Company also serves as the Chairman and CEO of Regen Biopharma, Inc. The sublease is on a month to month basis and rent payable to the Company by Regen Biopharma Inc is equal to the rent payable to the lessor by the Company and is to be paid in at such time specified in accordance with the original lease agreement between the Company and the lessor. On January 20, 2015 the sublease was amended retroactive to January 1, 2015 as follows:

The rent payable to Entest BioMedical, Inc. by the subtenant is equal to Five Thousand Dollars per month ($5,000) and is to be paid in at such time specified in accordance with the original lease agreement between the Entest BioMedical, Inc. (“Entest”) and the lessor. All charges for utilities connected with premises which are to be paid under the master lease shall be paid by Regen Biopharma, Inc. for the term of this sublease to the extent that such charges exceed the difference between the rent payable to the lessor by Entest under the master lease and the rent payable to Entest by Regen Biopharma, Inc.

19

On February 28, 2016, the Company purchased from a third party 3,500,000 shares of the Series A Preferred stock of Regen Biopharma, Inc for consideration consisting of $5,000 cash and 500,000 shares of the Company’s Series B Preferred Stock. On July 3, 2018 the Company sold the aforementioned 3,500,000 shares to Zander for consideration consisting of $35,000. David R. Koos, who serves as Chairman and Chief Executive Officer of Zander also serves as Chairman and Chief Executive Officer of Entest. Zander is under common control with Entest.

On July 3, 2018 Zander entered into a sublease agreement with Entest whereby Zander would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from Entest on a month to month basis for $6,000 per month beginning July 5, 2018.

David R. Koos, who serves as Chairman and Chief Executive Officer of Zander also serves as Chairman and Chief Executive Officer of Entest. Zander is under common control with Entest. 

NOTE 7.  INCOME TAXES

As of August 31, 2018
Deferred tax assets:
Net operating tax carry forwards	$	2,156,652
Other		-0-
Gross deferred tax assets		2,156,652
Valuation allowance		(2,156,652	)
Net deferred tax assets	$	-0-

As of  August 31, 2018  the Company has a Deferred Tax Asset of $2,156,652 completely attributable to net operating loss carry forwards of approximately $ 10,269,773(which expire 20 years from the date the loss was incurred) consisting of:

(a) $ 13,647 of Net Operating Loss carry forwards acquired in the reverse acquisition of Entest BioMedical, Inc., a California corporation, and

(b) $ 10,256,126 of Net Operating Loss carry forwards attributable to Entest BioMedical, Inc.

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. In addition, the reverse acquisition in which Entest BioMedical, Inc. was involved in 2009 has resulted in a change of control.  Internal Revenue Code Sec 382 limits the amount of income that may be offset by net operating loss (NOL) carryovers after an ownership change. As a result, the Company has recorded a valuation allowance reducing all deferred tax assets to $ -0-.

Income tax is calculated at the 21% Federal Corporate Rate.

NOTE 8.  ACQUISITION OF ENTEST CA

On July 10, 2009 the Company acquired 100% of Entest CA, a California corporation and wholly owned subsidiary of the Company, from BMSN for consideration consisting of (a) the issuance to BMSN of 10,000,000 newly issued common shares of Entest and (b) the return by Mr. Rick Plote of 10,000,000 shares of Entest’s common stock previously issued to him by Entest for cancellation.

20

NOTE 9.  ACQUISITION OF THE ASSETS OF PET POINTERS, INC.

On January 4, 2011 Entest CA acquired from Pet Pointers, Inc., a California corporation doing business as McDonald Animal Hospital (“Seller”), and Dr. Gregory McDonald DVM (“McDonald”) all the goodwill from McDonald and assets of Seller except cash and accounts receivables used in connection with the operation of a veterinary medical clinic located at 225 S. Milpas Street, Santa Barbara, CA 93103 (the "Business").

Consideration for the acquisition consisted of:

   I. $70,000 in cash

   II. $210,000 of the Company’s common shares valued at the closing price per share as of January 4, 2011

   III. Payment of no more than $78,000 to a creditor of the Seller to be paid in monthly installments of $1,500 per month

   IV. Payment of no more than $25,000 to additional creditors of the Seller to be paid in monthly installments of $825 per month

   V. Payment of $50,000 to McDonald on the first business day of the fourth month following the closing of the acquisition (“Closing”).

NOTE 10. DISPOSITION OF THE ASSETS OF PET POINTERS, INC.

On November 28, 2012 the “Company executed an agreement (“Agreement”) with Gregory McDonald ("McDonald"), Pet Pointers, Inc. ("Pet Pointer") whereby Mc Donald and Pet Pointer would acquire from the Company all assets (with the exception of cash and accounts receivable) utilized by the Company in the operation of the McDonald Animal Hospital, a full service veterinary clinic owned and operated by the Company and located in Santa Barbara, California (“McDonald Asset Sale”).

On October 10, 2012 a Complaint (“Complaint”) was filed in the Superior Court of the State of California against the Company and David Koos by McDonald, a former employee of the Company, alleging breach of contract and breach of the covenant of good faith and dealing in connection with the assumption of lease obligations by the Company in connection with the acquisition of the assets of Pet Pointers, Inc breach of contract and breach of the covenant of good faith and dealing in connection with an employment agreement enters into with McDonald inc connection with the Acquisition, breach of contract in connection with the Acquisition purchase agreement, breach of the covenant of good faith and dealing in connection with the Acquisition purchase agreement, implied indemnity in connection to amounts owed by McDonald to Anthony and Judi Marinelli, the Internal Revenue Service, and the California Franchise Tax Board, intentional misrepresentation, negligent misrepresentation , failure to pay wages and violations of Sections 2802, 203, and 2806 of the California Labor Code. The Complaint sought judgment for nominal damages, actual damages, compensatory damages, lost wages, compensation, expenses wage benefits and penalties pursuant to California Labor Code Sections 203 et al, 2802 and 2806, indemnification, accrued interest, punitive damages, costs of suit and attorney’s fees.

As consideration to the Company for the assets acquired, McDonald and Pet Pointers provided to the Company a General release whereby McDonald and Pet Pointer waive, release and discharge the Company and their respective assignees, officers, directors, shareholders, boards, owners, employees, attorneys, agents, trustors, trustees, beneficiaries, heirs, successors, and representatives from all known and unknown claims, demands, causes of action, attorney's fees, costs, or expenses including: 

21

(1) All claims relating to the Complaint.

(2) Those owed by McDonald to Anthony and Judi Marinelli which the Company became obligated to pay on McDonald’s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.

(3) Those amounts owed by McDonald to the Internal Revenue Service which the Company became obligated to pay on McDonald’s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.

(4) Those amounts owed by McDonald to the California Franchise Tax Board which the Company became obligated to pay on McDonald’s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.

Assets disposed of pursuant to the Agreement include approximately $4,840 of Property Plant and Equipment net of accumulated depreciation as well as all inventory held at the McDonald Animal Hospital.

Assets disposed of pursuant to the Agreement also include 

(i) Essentially all intellectual property, including computer software, utilized in connection with the operation of the McDonald Animal Hospital

(ii) All telephone numbers, fax numbers, service marks, trademarks, trade names, fictitious business names, websites, business email addresses, vendor lists, promotional materials, vendor records and any and all business records including, but not limited to, such items stored in computer memories, microfiche, paper record or by any other means relevant to the operation of the McDonald Animal Hospital.

(iii) All customer lists, customer contacts, and any and all customer records that are related to the McDonald Animal Hospital.

As a result of the agreement, the Company recorded a non-cash pre-tax charge for the impairment of goodwill recorded in connection with the acquisition of the McDonald Animal Hospital of approximately $405,000 for the quarter ended November 30, 2012.

Pursuant to the Agreement, the Company is obligated to make payment of $13,000 within five days of the Closing of the Agreement as such term is defined in the Agreement.

Pursuant to the Agreement, the Company agrees to waive, release and discharge McDonald and Pet Pointer from all known and unknown claims, demands, causes of action, attorney's fees, costs, or expenses.

NOTE 11. DECONSOLIDATION OF ZANDER THERAPEUTICS, INC.

On May 5, 2018, The Company declared the distribution on a pro rata basis as a dividend in kind of 3,000,000 of the common shares of Zander Therapeutics, Inc., par value $0.0001, currently owned by Entest Group, Inc. to:

(a) Holders of record of the outstanding common shares of the Company as of the record date, which is May 30, 2018.

(b) Holders of record of the shares of any outstanding series of the preferred shares of the Company as of the record date, which is May 30, 2018.

22

Shareholders of the Company shall receive one (1) common share of Zander Therapeutics, Inc. for each 17 common and/or preferred shares of the Company held as of the record date. The distribution of the 3,000,000 common shares of Zander Therapeutics, Inc. to the common and preferred shareholders of the Company occurred on June 11, 2018 ("Distribution Date").

As a result of the payment of the abovementioned property dividend, the Company’s percentage of ownership of Zander fell below 50% resulting in the deconsolidation of Zander as of the Distribution Date. As of the Distribution Date all assets and liabilities attributable to Zander were derecognized by the Company. The Company recognized a $10,034gain as a result of the deconsolidation. The Property dividend may be deemed to have occurred with a related party as the recipients were shareholders of Entest, including the Chairman and Chief Executive Officer of Entest and Regen Biopharma, Inc. which is a company under common control with Entest.

The Company’s remaining share of Zander , which consists of 5,000,000 shares of Zander’s Series M Preferred Stock (“Zander M Stock”) is accounted for under the Equity Method as of the Distribution Date. The Zander M Stock is carried a Fair Value and the carrying value is increased by the Company’s proportionate share of earnings of Zander and decreased by cash dividends paid by Zander as well as the Company’s proportionate share of losses of Zander up to the carrying value . As of August 31, 2018 the carrying value of the Zander M Stock has been decreased by the Company’s proportionate share of the losses of Zander and is 0. As of August 31, 2018 Entest beneficially owns 34.82% of the share equity of Zander.

5 million shares of Zander Series M Preferred Stock received by the Company on June 15, 2017 in consideration of services rendered has been valued by the Company as of the deconsolidation date utilizing the following inputs:

Fair Value of Intellectual Property	1,030
prepaid Expenses	168,000
Accounts Payable	454,493
Due from Entest	7,357
Accrued Expenses	2,148
Enterprise Value	633,028
Less: Total Debt	(463,998	)
Enterprise Value available to Shareholders	169,030
Per Share	0.012286

The Chairman and Chief Executive Officer of the Company and Zander is David R. Koos. Zander may be considered a related party of the Company.

SUMMARY INFORMATION FOR ZANDER THERAPEUTICS ,INC. FOR THE FISCAL YEAR ENDED AUGUST 31, 2018 

Revenue	0
Operating Loss	(2,801,376	)
Net Loss	(2,780,288	)
Portion of Net Loss attributable to Entest	(968,188	)

23

NOTE 12. COMMITMENTS AND CONTINGENCIES

On November 1, 2011, the Company entered into an agreement to lease approximately 2,320 square feet of office space beginning December 1, 2011 for a period of five years.

Rent to be charged to the Company pursuant to the lease is as follows:

$2,996 per month for the period beginning December 1, 2011 and ending November 30, 2012

$3,116 per month for the period beginning December 1, 2012 and ending November 30, 2013

$3,241 per month for the period beginning December 1, 2013 and ending November 30, 2014

$3,371 per month for the period beginning December 1, 2014 and ending November 30, 2015

$3,506 per month for the period beginning December 1, 2015 and ending November 30, 2016

On November 27, 2016 the lease was extended until November 30, 2021

Rent to be charged to the Company pursuant to the extension is as follows:

 $2,996 per month for the period beginning December 1, 2016 and ending November 30, 2017

$3,116 per month for the period beginning December 1, 2017 and ending November 30, 2018

$3,241 per month for the period beginning December 1, 2018 and ending November 30, 2019

$3,371 per month for the period beginning December 1, 2019 and ending November 30, 2020

$3,506 per month for the period beginning December 1, 2020 and ending November 30, 2021

This property is utilized as office space. The Company believes that the foregoing property is adequate to meet its current needs.

 NOTE 13. INVESTMENT SECURITIES

On February 28, 2017 the Company purchased 3,500,000 of the Series A Preferred shares of Regen Biopharma, Inc.for consideration consisting of $5,000 and 500,000 shares of the Company’s Series B Preferred stock.

The Series A Preferred shares of Regen Biopharma, Inc. described above constitute the Company’s sole investment securities as of August 31, 2017. The Company had no investment securities as of August 31, 2018

As of August 31, 2017:

	3,500,000		Series A Preferred shares of Regen Biopharma, Inc
	Basis		Fair Value	Total Unrealized Gains in Other Comprehensive Income	Net Unrealized Gain or (Loss) realized during the quarter  ended August 31, 2017
$	$5,000	$	$190,050	$185,050	$53,550

24

NOTE 14. STOCKHOLDERS EQUITY

The stockholders' equity section of the Company contains the following classes of capital stock as of August 31, 2018:

Common Stock:

$0.0001 par value, 500,000,000 shares authorized and 49,170,472 shares issued and outstanding as of August 31, 2018.

Preferred Stock:

$0.0001 par value 5,000,000 shares authorized of which:

(a)	100,000 are authorized as Series AA Preferred Stock of which 634 shares are issued and outstanding  as of  August 31, 2018  and
(b)	4,400,000 are authorized as Series B Preferred Stock of which 728,073 shares are issued and outstanding as of August 31, 2018 and
(c)	300,000  are authorized as Series AAA Preferred Stock of which 534 shares are issued and outstanding  as of  August 31, 2018.

Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series B Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.10 per share of Series B Preferred Stock (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series B Preferred Stock held by them.

If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series B Preferred Stock, then the entire net assets of the Company shall be distributed among the holders of the Series B Preferred Stock, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions August be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board..

Non Voting Convertible Preferred Stock having a $1.00 par value:

3,000,000 shares authorized of which 1,001,533 shares are issued and outstanding as of August 31 2018 .

Non Voting Convertible Preferred Stock shall convert at the option of the holder into shares of the corporation’s common stock at a conversion price equal to the greater of $0.01 per share or seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert.

“CLOSING PRICE" shall mean the closing bid price for the corporation’s common stock on the Principal Market on a Trading Day as reported by Bloomberg Finance L.P.

“PRINCIPAL MARKET" shall mean the principal trading exchange or market for the corporation’s common stock.

“TRADING DAY” shall mean a day on which the Principal Market shall be open for business.

NOTE 15. STOCK TRANSACTIONS

On September 8, 2017 the Company issued 2,500,000 Common Shares in connection with a conversion of 25,000 Non Voting Convertible Preferred Shares.

25

NOTE 16. SUBSEQUENT EVENTS

On October 2, 2018 Entest Group, Inc. (the “Company”) amended Article 4 of the Company’s Articles of Incorporation to be and read as follows:

4. Authorized Shares:

The aggregate number of shares, which the corporation shall have authority to issue, shall consist of 500,000,000 shares of Common Stock having a $.0001 par value, and 5,000,000 shares of Preferred Stock having a $.0001 par value and 3,000,000 shares of Non Voting Convertible Preferred Stock having a $1.00 par value.

Non Voting Convertible Preferred Stock shall convert at the option of the holder into shares of the corporation’s common stock at a conversion price equal to the greater of (i) $0.001 per share or (ii) seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert.

“CLOSING PRICE" shall mean the closing bid price for the corporation’s common stock on the Principal Market on a Trading Day as reported by Bloomberg Finance L.P.

“PRINCIPAL MARKET" shall mean the principal trading exchange or market for the corporation’s common stock.

“TRADING DAY” shall mean a day on which the Principal Market shall be open for business.

The Common and/or Preferred Stock of the Company may be issued from time to time without prior approval by the stockholders. The Common and/or Preferred Stock may be issued for such consideration as may be fixed from time to time by the Board of Directors- The Board of Directors may issue such share of Common and/or Preferred Stock in one or more series, with such voting powers, designations, preferences and rights or qualifications, limitations or restrictions thereof as shall be stated in the resolution or resolutions.”

On November 16, 2018 Entest terminated its lease on office space. The property has been assumed by BST Partners which is permitting the Company to utilize the space free of charge on a week to week basis.

BST Partners is controlled by David Koos, the Company’s Chairman and Chief Executive Officer.

On November 16, 2018 Zander Therapeutics Inc. and the Company agreed to terminate Zander’s sublease with the Company ( See Note 6) effective the rental period commencing November, 2018.

On November 16, 2018 Regen Biopharma Inc. and the Company agreed to terminate Regen’s sublease with the Company ( See Note 6) effective the rental period commencing November, 2018.

David R. Koos serves as Chairman and Chief Executive Officer of the Company, Zander Therapeutics, Inc. and Regen Biopharma Inc.

On November 16, 2018:

Entest Group, Inc. and David R. Koos agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to Koos by Entest from the beginning of time to November 30, 2018 by transferring to Koos 3,000,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company

Entest Group, Inc. and Blackbriar Partners (“BP) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BP by Entest from the beginning of time to November 30, 2018 by transferring to BP 20,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. BP is controlled by David Koos the Company’s sole officer and director.

Entest Group, Inc. and the Sherman Family Trust (“SFT”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to SFT by Entest from the beginning of time to November 30, 2018 by transferring to SFT 612,500 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

26

Entest Group, Inc. and Dunhill Ross Partners (“DR”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to DR by Entest from the beginning of time to November 30, 2018 by transferring to DR 12,500 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

Entest Group, Inc. and the Bio Technology Partners Business Trust (“BPBT”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BPBT by Entest from the beginning of time to November 30, 2018 by transferring to BPBT 412,500 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

Entest Group, Inc. and the Bio Matrix Scientific Group, Inc. (“BMSN”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BMSN by Entest from the beginning of time to November 30, 2018 by transferring to BMSN 5,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. David R. Koos serves as Chairman and Chief Executive Officer of the Company and BMSN.

Entest Group, Inc. and Bostonia Partners (“BSP”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BSP by Entest from the beginning of time to November 30, 2018 by transferring to BSP 212,500 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

Entest Group, Inc. and Regen Biopharma, Inc. (“RGBP”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to RGBP by Entest from the beginning of time to November 30, 2018 by transferring to RGBP 250,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

Entest Group, Inc. and Regen Biopharma, Inc. (“RGBP”) agreed to satisfy any and all rent prepaid by RGBP to Entest from the beginning of time to November 30, 2018 by transferring to RGBP 475,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

David R. Koos serves as Chairman and Chief Executive Officer of the Company and RGBP.

27

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

During the Registrant's most two most recent fiscal years there were no disagreements with AMC Auditing (“AMC”) , the Company’s independent registered public accounting firm, whether or not resolved, on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to AMC’s satisfaction, would have caused it to make reference to the subject matter of the disagreement in connection with its report on the Registrant's financial statements.

Item 9A. Controls and Procedures

a) Evaluation of disclosure controls and procedures.

The principal executive officer and principal financial officer have evaluated the Company’s disclosure controls and procedures as of August 31, 2018. Based on this evaluation, they have concluded that the disclosure controls and procedures were effective to ensure that the information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms and to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. David Koos is the Company’s CEO and acting CFO. He functions as the Company’s principal executive officer and principal financial officer.

b) Management’s annual report on internal control over financial reporting.

Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) promulgated under the Securities and Exchange Act of 1934. Rule 13a-15(f) defines internal control over financial reporting as follows:

“The term internal control over financial reporting is defined as a process designed by, or under the supervision of, the issuer's principal executive and principal financial officers, or persons performing similar functions, and effected by the issuer's board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the issuer;

Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the issuer are being made only in accordance with authorizations of management and directors of the issuer; and

Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the issuer's assets that could have a material effect on the financial statements.”

The Company’s internal control over financial reporting is a process designed under the supervision of the Company’s management to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial statements for external purposes in accordance with U.S. generally accepted accounting principles.

In designing and evaluating our disclosure controls and procedures, our management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only a reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met.

The Company’s management assessed the effectiveness of its internal control over financial reporting as of August 31, 2018 based on the framework in 2013 Committee of Sponsoring Organizations of the Treadway Commission, or COSO, framework. Based.” Based on its assessment, management believes that, as of August 31, 2018, the Company’s internal control over financial reporting is effective.

28

Management's report was not subject to attestation by the Company's registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the company to provide only management's report in this annual report. This exemption for smaller reporting companies provided under the temporary rules referenced above has been made permanent under Section 989G of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

(c) There have been no changes during the quarter ended August 31, 2018 in the Company’s internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

Item 10. Directors, Executive Officers and Corporate Governance

On June 19, 2009 the Board of Directors of the Company elected David R. Koos, a director of the Company and appointed Dr. Koos President, Chief Executive Officer, Secretary, Chief Financial Officer, Principal Accounting Officer of the Company. Dr. Koos resigned as Chief Financial Officer on March 31, 2010 and assumed the position of Acting Chief Financial Officer and Principal Accounting Officer on August 8, 2011 upon the resignation of Tammy L. Reynolds who served as Chief Financial Officer from the period from March 31, 2010 to August 8, 2011.

Education:

DBA - Finance (December 2003)

Atlantic International University

Ph.D. - Sociology (September 2003)

Atlantic International University

MA - Sociology (June 1983)

University of California - Riverside, California

Five Year Employment History:

Position:	Company Name:	Employment Dates:
Chairman, President, Chief Executive Officer, Secretary, Chief Financial Officer, Principal Account Officer	Entest Group, Inc	June 19, 2009 to the present
Chairman Chief Executive Officer, Secretary and Treasurer	Zander Therapeutics, Inc.	June 2015 to the Present
Chairman and CEO	Regen Biopharma, Inc.	April 24, 2012 to Present
Acting CFO	Regen Biopharma, Inc.	April 24, 2012 to February 11, 2015
President	Regen Biopharma, Inc.	May 29, 2013 to October 9, 2013
Chief Financial Officer, Principal Accounting Officer	Entest BioMedical, Inc	June 19, 2009 to March 31, 2010
Acting Chief Financial Officer, Principal Accounting Officer	Entest BioMedical, Inc	August 8, 2011 to the present
Chairman, President, CEO and Acting CFO	Bio-Matrix Scientific Group, Inc.	June 14, 2006 (Chairman) to Present; June 19, 2006 (President, CEO and Acting CFO); June 19, 2006 (Secretary) to Present

Code of Ethics

On November 11, 2009 we adopted a Code of Ethics pursuant to Section 406 of the Sarbanes-Oxley Act of 2002

Director Independence

29

Audit Committee and Audit Committee Financial Expert

The sole member of the Company’s board of Directors may not be considered independent as he is also its sole officer. The Company is not a "listed company" under Securities and Exchange Commission (“SEC”) rules and is therefore not required to have an audit committee comprised of independent directors. The Company does not currently have an audit committee, however, for certain purposes of the rules and regulations of the SEC and in accordance with the Sarbanes-Oxley Act of 2002, the Company’s  Board of Directors is deemed to be its  audit committee and as such functions as an audit committee and performs some of the same functions as an audit committee including: (1) selection and oversight of our independent accountant; (2) establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal controls and auditing matters; and (3) engaging outside advisors. The Board of Directors has determined that its member is  able to read and understand fundamental financial statements and has substantial business experience that results in that member's financial sophistication. Accordingly, the Board of Directors believes that its member has  the sufficient knowledge and experience necessary to fulfill the duties and obligations that an audit committee would have.

Nominating and Compensation Committees

The Company does not have standing nominating or compensation committees, or committees performing similar functions. The board of directors believes that it is not necessary to have a compensation committee at this time because the functions of such committee are adequately performed by the board of directors. The board of directors also is of the view that it is appropriate for the Company not to have a standing nominating committee because the board of directors has performed and will perform adequately the functions of a nominating committee. The Company is not a "listed company" under SEC rules and is therefore not required to have a compensation committee or a nominating committee.

Shareholder Communications

There has not been any defined policy or procedure requirements for stockholders to submit recommendations or nomination for directors. There are no specific, minimum qualifications that the board of directors believes must be met by a candidate recommended by the board of directors. Currently, the entire board of directors decides on nominees, on the recommendation of any member of the board of directors followed by the board’s review of the candidates’ resumes and interview of candidates. Based on the information gathered, the board of directors then makes a decision on whether to recommend the candidates as nominees for director. The Company does not pay any fee to any third party or parties to identify or evaluate or assist in identifying or evaluating potential nominee.

Because management and the Board of Directors  of the Company are the same people, the Board of Directors has determined not to adopt a formal methodology for communications from shareholders on the belief that any communication would be brought to the Board of Directors’ attention by virtue of the co-extensive capacities of the Board of Directors.

Executive Compensation

SUMMARY COMPENSATION TABLE

Name and Principal Position	Year		Salary ($)			Bonus ($)		Stock Awards ($)		Restricted Stock Awards ($)		Option Awards ($)		Non Equity Incentive Plan Compensation ($)		Nonqualified Deferred Compensation Earnings ($)		All Other Compensation ($)		Total ($)
David Koos Chairman, President and CEO		From September 1, 2017 to August 31, 2018	$	120,000	*		17,000	$			0		0		0		0		0	$137,000
		From September 1, 2016 to August 31, 2017	$	120,000	**		0		50		0		0		0		0		0	$120,050

*Does not include $88,000 in salary accrued but unpaid during prior periods paid to David Koos during the fiscal year ended August 31, 2018.

** Does not include $102,000 in salary accrued but unpaid during prior periods paid to David Koos during the fiscal year ended August 31, 2017. 

30

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth information known to the Company with respect to the beneficial ownership of each class of the Company’s capital stock as of November 15, 2018 for (1) each person known by the Company to beneficially own more than 5% of each class of the Company’s voting securities, (2) each executive officer, (3) each of the Company’s directors and (4) all of the Company’s executive officers and directors as a group. As of November 15, 2018 Entest BioMedical, Inc. had 49,170,472 common shares outstanding, 728, 073 Series B Preferred shares outstanding , 667 Series AA preferred shares outstanding, 534 Series AAA preferred shares outstanding, and 1001533 shares of the Company’s Non Voting Convertible Preferred Stock outstanding.

Based on 49,170,472 shares issued and outstanding as of November 15,2018  

Title of Class		Name and Address of Beneficial Owner	Amount and Nature  of Beneficial Owner		Percent of Class
	Common	David R. Koos* C/o Entest Group, Inc., Inc 4700 SPRING STREET, SUITE 203, LA MESA, CALIFORNIA, 91942		23,300,001		47.39	%
	Common	Life Sciences Journeys, Inc. 1106 2nd street Encinitas, CA ,92024		2,500,000		5.08	%
	Common	All Officers and Directors As a Group		23,300,001		47.39	%

*Includes 66,667 common shares owned by Bio-Matrix Scientific Group, Inc. (David Koos is CEO, President and Chairman of Bio-Matrix Scientific Group, Inc.). Includes 8,000,000 common shares owned by Regen Biopharma, Inc. (David Koos is CEO and Chairman of Regen Biopharma, Inc.)

Based on 728,009 shares issued and outstanding as of  November 15, 2018.

Title of Class	Name and Address of Beneficial Owner	Amount and Nature of Beneficial Owner		Percent of Class
Series B Preferred	David R. Koos* C/o Entest Group, Inc 4700 SPRING STREET, SUITE 203, LA MESA, CALIFORNIA, 91942		15,001		2.6	%
Series B Preferred	Thomas Ichim 9255 Town Center Dr San Diego, CA,92121		500,000		68.6	%
Series B Preferred	Thomas Donnelly 38 Miriam Road Denistone, NSW Australia		100,000		13.761	%
Series B Preferred	Linda Black 521 Garfield Ave Winter Park, FL 32789		100,000		13.761	%
Series B Preferred	All Officers and Directors as a Group*		15,001		2.6	%

*Includes 8,334 Series B Preferred  shares owned by Bio-Matrix Scientific Group, Inc. (David Koos is CEO, President and Chairman of Bio-Matrix Scientific Group, Inc.).

31

Based on 667 shares issued and outstanding as of  November 15, 2018    

Title of Class	Name and Address of Beneficial Owner	Amount and Nature  of Beneficial Owner		Percent of Class
Series AA Preferred Shares	David R. Koos C/o Entest Group, Inc 4700 SPRING STREET, SUITE 203, LA MESA, CALIFORNIA, 91942		667		100	%
Series AA Preferred Shares	All Officers and Directors As a Group		667		100	%

Based on 534 shares issued and outstanding as of  November 15, 2018   

Title of Class	Name and Address of Beneficial Owner	Amount and Nature  of Beneficial Owner		Percent of Class
Series AAA Preferred Shares	David R. Koos C/o Entest Bio Medical Inc., Inc 4700 SPRING STREET, SUITE 203, LA MESA, CALIFORNIA, 91942		534		100	%
Series AAA Preferred Shares	All Officers and Directors As a Group		534		100	%

Based on 1,001,533 shares issued and outstanding as of  November 15, 2018   

Title of Class	Name and Address of Beneficial Owner	Amount and Nature of Beneficial Owner		Percent of Class
Non Voting Convertible Preferred	Bio Technology Partners Business Trust 8130 Las Mesa Blvd Las Mesa CA 91941		124,000		12.38	%
Non Voting Convertible Preferred	David R. Koos C/o Entest Bio Medical Inc., Inc 4700 SPRING STREET, SUITE 203, LA MESA, CALIFORNIA, 91942*		185,852		18.55	%
Non Voting Convertible Preferred	Bostonia Partners 1204 Tangerine El Cajon, CA,92021		327681		32.7	%
Non Voting Convertible Preferred	Dunhill Ross Partners La Mesa CA		165,000		16.4	%
Non Voting Convertible Preferred	Sherman Family Trust La Mesa, CA		199,000		19.8	%
Non Voting Convertible Preferred	All Officers and Directors as a Group*		185,852		18.55	%

* Includes 185,852 shares owned by Regen Biopharma, Inc. David R. Koos is Chairman and Chief Executive Officer of both Entest Biomedical, Inc. and Regen Biopharma, Inc.

32

Item 13. Certain Relationships and Related Transactions, and Director Independence

As of August 31, 2018 the Company remains indebted to David R. Koos , the Company’s sole officer and director, in the principal amount of $2,600 due and payable in whole or in part at the demand of David Koos and bearing simple interest at a rate of 15% per annum.

As of August 31, 2018 the Company remains indebted to Blackbriar Partners in the principal amount of $11,600 of which $1,000 is  due and payable February 17, 2018 and bears simple interest at a rate of 10%per annum and of which $7,000 is due and payable February 28, 2018 and bears simple interest at a rate of 10% per annum , of which$3,000 is due and payable May 4, 2019 and bears simple interest at a rate of 10% per annum and of which $600 is due and payable August 20, 2019 and bears simple interest at a rate of 10% per annum.

Blackbriar Partners is controlled by David R. Koos , the Company’s sole officer and director.

As of August 31, 2018 the Company remains indebted to Regen Biopharma, Inc. in the principal amount of $4,551 due and payable in whole or in part at the demand of the holder and bearing simple interest at a rate of 10% per annum. David R. Koos , the Company’s sole officer, serves as Chairman and Chief Executive officer of Regen Biopharma, Inc.

On October 1, 2014 Regen Biopharma Inc. entered into an agreement to sublease approximately 2,320 square feet of office space from the Company. Entest Biomedical Inc. is under common control with Regen Biopharma, Inc. as the Chairman and CEO of the Company also serves as the Chairman and CEO of Regen Biopharma, Inc. The sublease is on a month to month basis and rent payable to the Company by Regen Biopharma Inc is equal to the rent payable to the lessor by the Company and is to be paid in at such time specified in accordance with the original lease agreement between the Company and the lessor. On January 20, 2015 the sublease was amended retroactive to January 1, 2015 as follows:

The rent payable to Entest BioMedical, Inc. by the subtenant is equal to Five Thousand Dollars per month ($5,000) and is to be paid in at such time specified in accordance with the original lease agreement between the Entest BioMedical, Inc. (“Entest”) and the lessor. All charges for utilities connected with premises which are to be paid under the master lease shall be paid by Regen Biopharma, Inc. for the term of this sublease to the extent that such charges exceed the difference between the rent payable to the lessor by Entest under the master lease and the rent payable to Entest by Regen Biopharma, Inc.

On February 28, 2016, the Company purchased from a third party 3,500,000 shares of the Series A Preferred stock of Regen Biopharma, Inc for consideration consisting of $5,000 cash and 500,000 shares of the Company’s Series B Preferred Stock. On July 3, 2018 the Company sold the aforementioned 3,500,000 shares to Zander for consideration consisting of $35,000. David R. Koos, who serves as Chairman and Chief Executive Officer of Zander also serves as Chairman and Chief Executive Officer of Entest. Zander is under common control with Entest.

On July 3, 2018 Zander entered into a sublease agreement with Entest whereby Zander would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from Entest on a month to month basis for $6,000 per month beginning July 5, 2018.

David R. Koos, who serves as Chairman and Chief Executive Officer of Zander also serves as Chairman and Chief Executive Officer of Entest. Zander is under common control with Entest.

On November 16, 2018 Entest terminated its lease on office space. The property has been assumed by BST Partners which is permitting the Company to utilize the space free of charge on a week to week basis.

BST Partners is controlled by David Koos, the Company’s Chairman and Chief Executive Officer.

33

On November 16, 2018 Zander Therapeutics Inc. and the Company agreed to terminate Zander’s sublease with the Company effective the rental period commencing November, 2018.

On November 16, 2018 Regen Biopharma Inc. and the Company agreed to terminate Regen’s sublease with the Company effective the rental period commencing November, 2018.

David R. Koos serves as Chairman and Chief Executive Officer of the Company, Zander Therapeutics, Inc. and Regen Biopharma Inc.

On November 16, 2018:

Entest Group, Inc. and David R. Koos agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to Koos by Entest from the beginning of time to November 30, 2018 by transferring to Koos 3,000,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

Entest Group, Inc. and Blackbriar Partners (“BP) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BP by Entest from the beginning of time to November 30, 2018 by transferring to BP 20,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. BP is controlled by David Koos the Company’s sole officer and director.

Entest Group, Inc. and the Bio Matrix Scientific Group, Inc. (“BMSN”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BMSN by Entest from the beginning of time to November 30, 2018 by transferring to BMSN 5,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. David R. Koos serves as Chairman and Chief Executive Officer of the Company and BMSN.

Entest Group, Inc. and Regen Biopharma, Inc. (“RGBP”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to RGBP by Entest from the beginning of time to November 30, 2018 by transferring to RGBP 250,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

Entest Group, Inc. and Regen Biopharma, Inc. (“RGBP”) agreed to satisfy any and all rent prepaid by RGBP to Entest from the beginning of time to November 30, 2018 by transferring to RGBP 475,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

David R. Koos serves as Chairman and Chief Executive Officer of the Company and RGBP.

Director Independence

Audit Committee and Audit Committee Financial Expert

The Company’s  sole director may not be considered independent as  he is also an  officer. The Company is not a "listed company" under Securities and Exchange Commission (“SEC”) rules and is therefore not required to have an audit committee comprised of independent directors. The Company does not currently have an audit committee, however, for certain purposes of the rules and regulations of the SEC and in accordance with the Sarbanes-Oxley Act of 2002, the Company’s  Board of Directors is deemed to be its  audit committee and as such functions as an audit committee and performs some of the same functions as an audit committee including: (1) selection and oversight of our independent accountant; (2) establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal controls and auditing matters; and (3) engaging outside advisors. The Board of Directors has determined that its sole member is able to read and understand fundamental financial statements and has substantial business experience that results in the member's financial sophistication. Accordingly, the Board of Directors believes that its member has the sufficient knowledge and experience necessary to fulfill the duties and obligations that an audit committee would have.

34

Nominating and Compensation Committees

The Company does not have standing nominating or compensation committees, or committees performing similar functions. The Board of Directors believes that it is not necessary to have a compensation committee at this time because the functions of such committee are adequately performed by the board of directors. The Board of Directors also is of the view that it is appropriate for the Company not to have a standing nominating committee because the Board of Directors has performed and will perform adequately the functions of a nominating committee. The Company is not a "listed company" under SEC rules and is therefore not required to have a compensation committee or a nominating committee.

Shareholder Communications

There has not been any defined policy or procedure requirements for stockholders to submit recommendations or nomination for directors. There are no specific, minimum qualifications that the board of directors believes must be met by a candidate recommended by the board of directors. Currently, the entire board of directors decides on nominees, on the recommendation of any member of the board of directors followed by the board’s review of the candidates’ resumes and interview of candidates. Based on the information gathered, the board of directors then makes a decision on whether to recommend the candidates as nominees for director. The Company does not pay any fee to any third party or parties to identify or evaluate or assist in identifying or evaluating potential nominee.

The Board of Directors has determined not to adopt a formal methodology for communications from shareholders on the belief that any communication would be brought to the board of directors’ attention by virtue of communication with management.

Item 14. Principal Accounting Fees and Services

The following table sets forth the aggregate fees billed to us by AMC Auditing during the period beginning September 1, 2017 and ending August 31, 2018:

Audit Fees	$	15,000
Audit Related Fees		13,546
Tax Fees		0
All Other Fees		0
	$	28,546

Audit Fees: Aggregate fees billed for professional services rendered for the audit of the Company's annual financial statements.

Audit Related Fees:   Aggregate fees billed for professional services rendered for assurance and related services that were reasonably related to the performance of the audit or review of our financial statements and are not reported under “Audit Fees” above. During the year ended August 31, 2017 these fees were primarily derived from review of financial statements in the Company's Form 10Q Reports.

All services listed were pre-approved by the Board of Directors, functioning as the Audit Committee in accordance with Section 2(a) 3 of the Sarbanes-Oxley Act of 2002.

The Board has considered whether the services described above are compatible with maintaining the independent accountant's independence and has determined that such services have not adversely affected the independence of AMC Auditing.

35

Item 15. Exhibit Index

31.1	CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANESE-OXLEY ACT OF 2002
31.2	CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANESE-OXLEY ACT OF 2002
32.1	CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
32.2	CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
3(i)		TEXT OF CERTIFICATE OF AMENDMENT Name Change( (a) )
10.1		Stock Purchase Agreement (b)
3(ii)		TEXT OF CERTIFICATE OF AMENDMENT ART. 4(c)
99.1		Stock purchase Agreement sale of control shares (d)

(a) Incorporated by reference to Exhibit 3(i) of the Company’s Form 8-K dated 1/10/2018

(b) Incorporated by reference to Exhibit 10.1 of the Company’s Form 8-K dated 7/5/2018

(c) Incorporated by reference to Exhibit 3(i) of the Company’s Form 8-K dated 10/3/2018

(d) Incorporated by reference to Exhibit 10.1 of the Company’s Form 8-K filed 11/20/2018

36

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Entest BioMedical, Inc.
By:	/s/David R. Koos
	Name: David R. Koos
	Title: President, Chairman, Chief Executive Officer
	Date: November 21, 2018.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on November 25, 2014.

By:	/s/ David R. Koos
	Name: David R. Koos
	Title: President, Chairman of the Board of Directors, Chief Executive Officer, Acting Chief Financial Officer
	Date: November 21, 2018.

37

EX-31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David R. Koos, certify that:

1. I have reviewed this annual report on Form 10-K for the year ended August 31, 2018 of Entest Group, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant’s, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles:

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.  

Dated: November 21, 2018	By:	/s/ David R. Koos
		David R. Koos
		Chief Executive Officer

EX-31.2

EXHIBIT 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David R. Koos, certify that:

1. I have reviewed this annual report on Form 10-K for the year ended August 31, 2018 of Entest Group, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant’s, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles:

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 21, 2018	By:	/s/ David R. Koos
		David R. Koos
		Chief Financial Officer

EX-32.1

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Entest Group, Inc. on Form 10-K for the year ended August 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David R. Koos, Chief Executive Officer certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. 

Dated: November 21, 2018	By:	/s/ David R. Koos
		David R. Koos
		Chief Executive Officer

EX-32.2

EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Entest Group, Inc. on Form 10-K for the year ended August 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David R. Koos, Chief Financial Officer certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 21, 2017	By:	/s/ David R. Koos
		David R. Koos
		Chief Financial Officer

XML

Document and Entity Information - USD ($)	12 Months Ended
	Aug. 31, 2018	Nov. 16, 2018	Feb. 28, 2018
Document And Entity Information
Entity Registrant Name	ENTEST GROUP, INC.
Entity Central Index Key	0001449447
Document Type	10-K
Document Period End Date	Aug. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	true
Entity Public Float			$ 470,842
Entity Common Stock, Shares Outstanding		49,170,472
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018

XML

Consolidated Balance Sheet - USD ($)	Aug. 31, 2018	Aug. 31, 2017
Current Assets
Cash	$ 267	$ 86,559
Accrued Interest Receivable	1,040	908
Current Portion of Prepaid Expenses	8,000	58,652
Accrued Rent Receivable	0	0
Total Current Assets	9,307	146,119
OTHER ASSETS
Available for Sale Securities	0	190,050
Long Term Portion Prepaid Expenses	0	0
TOTAL ASSETS	9,307	336,169
Current Liabilities
Accounts Payable	28,447	28,446
Notes Payable	19,601	13,501
Due to Other	8,000	8,000
Unearned Rental Income	17,000	0
Bank Overdraft	66	0
Accrued Expenses	181,904	269,398
Total Current Liabilities	255,018	319,345
TOTAL LIABILITIES	255,018	319,345
STOCKHOLDERS' EQUITY
Common Stock, authorized 500,000,000 shares as of August 31, 2017 and August 31, 2018; issued and outstanding 46,670,472(par value $0.0001) as of August 31, 2017 and 49,170,472 as of August 31, 2018	4,911	4,661
Additional Paid in Capital	8,729,236	7,191,000
Contributed Capital	274,662	274,662
Accumulated Deficit	(10,256,126)	(8,721,498)
Accumulated Other Comprehensive Income	0	185,050
Total Stockholders' Equity Entest Biomedical, Inc.	(245,711)	(39,519)
Non Controlling Interest Zander Therapeutics Inc.	0	56,343
Stockholders Equity	(245,711)	16,824
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY	9,307	336,169
NonVoting [Member]
STOCKHOLDERS' EQUITY
Preferred Stock	1,001,533	1,026,533
Series AA
STOCKHOLDERS' EQUITY
Preferred Stock	4,911	4,661
Series B
STOCKHOLDERS' EQUITY
Preferred Stock	0	0
Series AAA
STOCKHOLDERS' EQUITY
Preferred Stock	$ 73	$ 73

XML

Consolidated Balance Sheet (Parenthetical) - $ / shares	Aug. 31, 2018	Aug. 31, 2017	Feb. 28, 2017
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	49,170,472	46,670,472
Common stock, shares outstanding	49,170,472	46,670,472
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series AAA
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	300,000	300,000
Preferred stock, shares issued	534	534
Preferred stock, shares outstanding	534	534
Series B
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	4,400,000	4,400,000
Preferred stock, shares issued	728,009	728,009	500,000
Preferred stock, shares outstanding	728,009	728,009
Series AA
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	100,000	100,000
Preferred stock, shares issued	667	667
Preferred stock, shares outstanding	667	667
NonVoting [Member]
Preferred stock, par value	$ 1.00	$ 1.00
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	1,001,533	1,026,533
Preferred stock, shares outstanding	1,001,533	1,026,533

XML

Consolidated Statement of Operations - USD ($)	12 Months Ended
	Aug. 31, 2018	Aug. 31, 2017
REVENUES
TOTAL REVENUE	$ 0	$ 0
COSTS AND EXPENSES
Research and Development	949,584	124,770
Rent Costs	37,032	37,482
General and Administrative	224,263	225,804
Consultant's Expenses	310,020	263,823
Total Costs and Expenses	1,520,899	651,879
OPERATING LOSS	(1,520,899)	(651,879)
OTHER INCOME AND EXPENSE
Rental Income	66,000	60,000
Interest Income	132	1,056
Gain on Write Off of Accounts Payable	0	76,697
Loss on Issuance of Stock Below Fair Value	0	(107,700)
Gain on Deconsolidation of Zander	10,034	0
Equity in Losses of Zander	(61,428)	0
Gain on Sale of Securities	30,000	0
Interest Expense	(1,323)	(42,966)
TOTAL OTHER INCOME AND EXPENSE	43,415	(12,913)
LOSS BEFORE INCOME TAXES	(1,477,484)	(664,792)
Income Taxes	0	0
NET LOSS
NET LOSS from continuing Operations	(1,477,484)	(664,792)
Less: (Net Income) Loss attributable to non controlling interest in Zander Therapeutics, Inc.	0	105,374
NET LOSS available to common shareholders	$ (1,477,484)	$ (559,418)
BASIC AND DILUTED EARNINGS (LOSS) PER SHARE FROM CONTINUING OPERATIONS	$ (0.030)	$ (0.013)
WEIGHTED AVERAGE NUMBER COMMON SHARES OUTSTANDING	48,987,813	42,551,431

XML

Consolidated Statement of Comprehensive Income - USD ($)	12 Months Ended
	Aug. 31, 2018	Aug. 31, 2017
Statement of Comprehensive Income [Abstract]
Net Income (Loss)	$ (1,477,484)	$ (664,792)
Add:
Unrealized Gains on Securities	0	277,100
Less:
Unrealized Losses on Securities	0	(92,050)
Comprehensive Income attributable to Non Controlling Interest	0	0
Total Other Comprehensive income (Loss)	0	185,050
Comprehensive Income	$ (1,477,484)	$ (479,742)

XML

Consolidated Statement of Cash Flows - USD ($)	12 Months Ended
	Aug. 31, 2018	Aug. 31, 2017
OPERATING ACTIVITIES
Net (Loss)	$ (1,477,484)	$ (664,792)
Adjustments to reconcile net loss to net cash used by operating activities:
Increase (Decrease) in stock of subsidiary issued to employees	0	150
Increase (Decrease) in stock of subsidiary issued to consultants	0	300
Increase (Decrease) in Additional paid in capital	0	64,709
Increase (Decrease) in Issuance of Stock below Fair Value	0	107,700
Increase (Decrease) in Preferred Stock issued for expenses	0	185,852
Increase (Decrease) in Preferred Stock issued to Consultants	0	70
(Increase) Decrease in Gain attributable to Deconsolidation	(10,034)	0
(Increase) Decrease Cash Lost in Deconsolidation	(332,638)	0
Equity in Losses of Zander	61,428	0
Increase (Decrease) Common Stock issued to Consultants	0	110,475
Changes in Operating Assets and Liabilities
(Increase) Decrease in Prepaid Expenses	(117,388)	(50,652)
Increase(Decrease) in Unearned Rent	17,000	0
Increase (Decrease) in Accounts Payable	454,494	(83,716)
(Increase) Decrease in Accrued Rental Income Receivable	0	15,000
Increase (Decrease) in Accrued Expenses	(85,347)	(157,566)
(Increase) Decrease in Accrued Interest Receivable	(132)	(909)
(Increase) Decrease in Notes Receivable	0	0
Net Cash Provided (Used) in Operating Activities	(1,490,101)	(473,380)
Net Cash Provided ( Used) in Investing Activities:
Securities Purchased for Cash	0	(5,000)
Gain on Sale of Securities received prior to deconsolidation	(2,357)	0
Net Cash Provided (Used In) Investing Activities	(2,357)	(5,000)
FINANCING ACTIVITIES
Common Stock issued for cash	0	15,000
Common Stock of Subsidiary issued for cash	1,400,000	120,000
Increase (Decrease) in Notes Payable	6,100	428,580
Increase(Decrease) Bank Overdraft	66	0
Increase (Decrease) in Contributed Capital	0	500
Net Cash Provided by Financing Activities	1,406,166	564,080
Net (Decrease) Increase in Cash	(86,292)	85,700
Cash at Beginning of Period	86,559	859
Cash at End of Period	267	86,559
Supplemental Disclosure of Non CashInvesting and Financing Activities:
Common Stock Issued for Debt	0	30,000
Preferred Stock issued for Debt	$ 0	$ 840,681

XML

Consolidated Statement of Stockholders' Equity - USD ($)	Common Stock	Series AA Preferred	Series AAA Preferred	Series B Preferred	Non Voting Convertible Preferred	Additional Paid-In Capital	Contributed Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit during the Development Stage	Non Controlling interest In Subsidiary	Total
Beginning balance, Shares at Aug. 31, 2016	40,170,472
Beginning balance, Amount at Aug. 31, 2016	$ 4,011	$ 667	$ 533	$ 28,009	$ 0	$ 6,148,054	$ 274,162		$ (7,405,099)		$ (978,869)
Common Shares issued to Consultant	100,000
Common Shares issued to Consultant, Amount	$ 10					4,490					4,500
Common Shares issued for Debt, Shares	1,000,000
Common Shares issued for Debt, Amount	$ 100					9,900					10,000
Common Shares issued for Debt, Shares	2,000,000
Common Shares issued for Debt, Amount	$ 200					19,800					20,000
Common Shares issued to Consultant	100,000
Common Shares issued to Consultant, Amount	$ 10					4,810					4,820
Series B Preferred shares issued to consultant				500,000
Series B Preferred shares issued to consultant, Amount				$ 50							50
Series B Preferred shares issued to consultant				100,000
Series B Preferred shares issued to consultant, Amount				$ 10							10
Series B Preferred shares issued to consultant				100,000
Series B Preferred shares issued to consultant, Amount				$ 10							10
Common Stock Issued for Cash	750,000
Common Stock Issued for Cash, Amount	$ 75					14,925					15,000
Common Stock of Subsidiary sold for Cash						20,000					20,000
Common Shares issued to Consultant	100,000
Common Shares issued to Consultant, Amount	$ 10					3,390					3,400
Shares issued for accrued expenses					83,000
Shares issued for accrued expenses, Amount					$ 83,000						83,000
Shares issued for Debt, Shares					840,681
Shares issued for Debt, Amount					$ 840,681						840,681
Beneficial Conversion Feautures recognized						576,804					576,804
Amortization of Beneficial Conversion Feauture									(576,804)		(576,804)
Preferred Shares of Subsidiary issued to consultants						100					100
Preferred Shares of Subsidiary issued to employees						150					150
Common Stock of Subsidiary issued for Cash						100,000					100,000
Common Shares of Subsidiary issued to Consultant						50					50
Preferred Shares of Subsidiary issued to consultants						10					10
Common Shares issued to Consultant	2,450,000
Common Shares issued to Consultant, Amount	$ 245					97,510					97,755
Shares issued for accrued expenses					102,852
Shares issued for accrued expenses, Amount					$ 102,852						102,852
Beneficial Conversion Feautures recognized						74,801					74,801
Amortization of Beneficial Conversion Feauture									(74,801)		(74,801)
Preferred Shares of Subsidiary issued to consultants						140					140
Restricted Stock Expense Recognized						64,709					64,709
Accumulated Other Comprehensive Income Recognized								185,050			185,050
Loss on Issuance below Fair Value						107,000					107,000
Net Loss for Year									(664,792)		(664,792)
Non Controlling Interest in Subsidiary						(56,343)					(56,343)
Increase in Contributed Capital Year							500				500
Ending balance, Shares at Aug. 31, 2017	46,670,472	667	533	728,009	1,026,533
Ending balance, Amount at Aug. 31, 2017	$ 4,661	$ 0	$ 0	$ 73	$ 1,026,533	7,191,000	274,662	185,050	(8,721,498)	56,343	16,824
Common Shares issued for NonVoting Convertible Preferred Shares	2,500,000				(25,000)
Common Shares issued for NonVoting Convertible Preferred Shares, Amount	$ 250				$ (25,000)	24,750					0
Common Stock of Subsidiary issued for Cash						900,000					900,000
Common Stock of Subsidiary issued for Cash						200,000					200,000
Common Shares of Subsidiary issued to Consultant						300,000					300,000
Declaration of property Dividend									(57,143)		(57,143)
Payment of Property Dividend						57,143					57,143
Elimination of Noncontrolling Interest upon deconsolidation						56,343				(56,343)	0
Sale of Securities of Securities Available for Sale								(185,050)			(185,050)
Net Loss for Year									(1,477,484)		(1,477,484)
Increase in Contributed Capital Year											0
Ending balance, Shares at Aug. 31, 2018	49,170,472	667	533	728,009	1,001,533
Ending balance, Amount at Aug. 31, 2018	$ 4,911	$ 0	$ 0	$ 73	$ 1,001,533	$ 8,729,236	$ 274,662	$ 0	$ (10,256,126)	$ 0	$ (245,711)

XML

Organization and Description of Business

12 Months Ended

Aug. 31, 2018

Accounting Policies [Abstract]

Organization and Description of Business

NOTE 1.  ORGANIZATION AND DESCRIPTION OF BUSINESS

Entest Biomedical, Inc ( The “Company”) was incorporated in the State of Nevada on September 24, 2008 as JB Clothing Corporation.  Until July 10, 2009, the Company’s principal business objective was the offering of active/leisure fashion design clothing.

On July 10, 2009 the Company abandoned its efforts in the field of active/leisure fashion design clothing when it acquired 100% of the share capital of Entest BioMedical, Inc., a California corporation, (“Entest CA”).

On June 18, 2015 the Company formed Zander Therapeutics, Inc. (“Zander”) , a Nevada corporation. As of August 31, 2018 Entest owns Zander 34.82% of Zander.

On February 12, 2018 the Company changed its name to The Entest Group, Inc.

As of August 31, 2018 the Company is a “Shell Company” as such term is defined in Rule 12(b)(2) promulgated under the Securities and Exchange Act of 1934 . This Rule defines as Shell Company as a company that has:

(1) No or nominal operations; and

(2) Either:

(i) No or nominal assets;

(ii) Assets consisting solely of cash and cash equivalents; or

(iii) Assets consisting of any amount of cash and cash equivalents and nominal other assets.

XML

Summary of Significant Accounting Policies

12 Months Ended

Aug. 31, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

NOTE 2.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. BASIS OF ACCOUNTING

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted an August 31 fiscal year-end.   The Company recognizes revenue from services and product sales when the following four revenue recognition criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the selling price is fixed or determinable, and collectability is reasonably assured.

B. PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the accounts of Entest CA, the Company’s wholly owned subsidiary. These financial statement also include the accounts of Zander up to June 10, 2018. Significant inter-company transactions have been eliminated.

C. USE OF ESTIMATES

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

D. CASH EQUIVALENTS

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

E. PROPERTY AND EQUIPMENT

As of August 31, 2018 Property and Equipment consists of $0

F. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

Level 1:  Quoted prices in active markets for identical assets or liabilities

Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company’s financial instruments as of August 31, 2018 consisted of $ 19,601 of Notes Payable and $8,000 due to TheraCyte, Inc.. The fair value of all of the Company’s financial instruments as of August 31, 2018 were valued according to the Level 3 input. The carrying amount of the financial instruments is equal to the fair value as determined by the Company.

The Company has determined that there are no Level 1 or Level 2 inputs for determining the fair value of the Company’s financial instruments. Fair value was determined by the Company utilizing its own assumptions and estimation. There were no transfers between levels for the period presented.

G. INCOME TAXES

The Company accounts for income taxes using the liability method prescribed by ASC 740, “ Income Taxes. ” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company applied the provisions of ASC 740-10-50, “Accounting for Uncertainty in Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of August 31, 2018 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

H.  BASIC EARNINGS (LOSS) PER SHARE

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. All convertible debt has an anti-dilutive effect on the EPS, therefore Diluted earnings per share are the same as basic earnings per share.

XML

Recent Accounting Pronouncements

12 Months Ended

Aug. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Recent Accounting Pronouncements

NOTE 3.  RECENT ACCOUNTING PRONOUNCEMENTS

In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as "Development Stage Entities" (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard.

The following accounting standards updates were recently issued and have not yet been adopted by the Company. These standards are currently under review to determine their impact on the Company’s consolidated financial position, results of operations, or cash flows.

In May 2014, FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. The revenue recognition standard affects all entities that have contracts with customers, except for certain items. The new revenue recognition standard eliminates the transaction-and industry-specific revenue recognition guidance under current GAAP and replaces it with a principle-based approach for determining revenue recognition. Public entities are required to adopt the revenue recognition standard for reporting periods beginning after December 15, 2016, and interim and annual reporting periods thereafter. Early adoption is not permitted for public entities. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.

In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award's grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. 

In August2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure.

XML

Going Concern

12 Months Ended

Aug. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Going Concern

NOTE 4.  GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $10,256,126 during the period from August 22, 2008 (inception) through August 31, 2018. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Management intends to seek business opportunities to review and analyze for purposes of effecting a merger, acquisition or other business combination with an operating company business.

XML

Notes Payable

12 Months Ended

Aug. 31, 2018

Debt Disclosure [Abstract]

Notes Payable

NOTE 5.  NOTES PAYABLE  

As of August 31, 2018

Notes Payable:

David Koos (See Note 6)	$	2,600
Dunhill Ross Partners, Inc.	$	850
Blackbriar Partners (See Note 6)		11,600
Regen Biopharma, Inc (See Note 6)		4,551
Total	$	19,601

$1,000 lent to the Company by Blackbriar Partners is due and payable February 17, 2018 and bears simple interest at a rate of 10% per annum

$7,000 lent to the Company by Blackbriar Partners is due and payable February 28, 2018 and bears simple interest at a rate of 10% per annum.

$3,000 lent to the Company by Blackbriar Partners is due and payable May 4, 2019 and bears simple interest at a rate of 10% per annum.

$600 lent to the Company by Blackbriar Partners is due and payable August 20, 2019 and bears simple interest at a rate of 10% per annum.

Blackbriar Partners is controlled by David R. Koos , the Company’s sole officer and director.

As of August 31, 2018 the Company remains indebted to David R. Koos , the Company’s sole officer and director, in the principal amount of $2,600 due and payable in whole or in part at the demand of David Koos and bearing simple interest at a rate of 15% per annum.

Amounts due to Regen Biopharma Inc. as of August 31, 2018 are due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum. David R. Koos , the Company’s sole officer, serves as Chairman and Chief Executive officer of Regen Biopharma, Inc.

XML

Related Party Transactions

12 Months Ended

Aug. 31, 2018

Related Party Transactions [Abstract]

Related Party Transactions

NOTE 6.  RELATED PARTY TRANSACTIONS

As of August 31, 2018 the Company remains indebted to David R. Koos , the Company’s sole officer and director, in the principal amount of $2,600 due and payable in whole or in part at the demand of David Koos and bearing simple interest at a rate of 15% per annum.

As of August 31, 2018 the Company remains indebted to Blackbriar Partners in the principal amount of $11,600 of which $1,000 is  due and payable February 17, 2018 and bears simple interest at a rate of 10%per annum and of which $7,000 is due and payable February 28, 2018 and bears simple interest at a rate of 10% per annum , of which$3,000 is due and payable May 4, 2019 and bears simple interest at a rate of 10% per annum and of which $600 is due and payable August 20, 2019 and bears simple interest at a rate of 10% per annum.

Blackbriar Partners is controlled by David R. Koos , the Company’s sole officer and director.

As of August 31, 2018 the Company remains indebted to Regen Biopharma, Inc. in the principal amount of $4,551 due and payable in whole or in part at the demand of the holder and bearing simple interest at a rate of 10% per annum. David R. Koos , the Company’s sole officer, serves as Chairman and Chief Executive officer of Regen Biopharma, Inc.

 On October 1, 2014 Regen Biopharma Inc. entered into an agreement to sublease approximately 2,320 square feet of office space from the Company. Entest Biomedical Inc. is under common control with Regen Biopharma, Inc. as the Chairman and CEO of the Company also serves as the Chairman and CEO of Regen Biopharma, Inc. The sublease is on a month to month basis and rent payable to the Company by Regen Biopharma Inc is equal to the rent payable to the lessor by the Company and is to be paid in at such time specified in accordance with the original lease agreement between the Company and the lessor. On January 20, 2015 the sublease was amended retroactive to January 1, 2015 as follows:

The rent payable to Entest BioMedical, Inc. by the subtenant is equal to Five Thousand Dollars per month ($5,000) and is to be paid in at such time specified in accordance with the original lease agreement between the Entest BioMedical, Inc. (“Entest”) and the lessor. All charges for utilities connected with premises which are to be paid under the master lease shall be paid by Regen Biopharma, Inc. for the term of this sublease to the extent that such charges exceed the difference between the rent payable to the lessor by Entest under the master lease and the rent payable to Entest by Regen Biopharma, Inc.

On February 28, 2016, the Company purchased from a third party 3,500,000 shares of the Series A Preferred stock of Regen Biopharma, Inc for consideration consisting of $5,000 cash and 500,000 shares of the Company’s Series B Preferred Stock. On July 3, 2018 the Company sold the aforementioned 3,500,000 shares to Zander for consideration consisting of $35,000. David R. Koos, who serves as Chairman and Chief Executive Officer of Zander also serves as Chairman and Chief Executive Officer of Entest. Zander is under common control with Entest.

On July 3, 2018 Zander entered into a sublease agreement with Entest whereby Zander would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from Entest on a month to month basis for $6,000 per month beginning July 5, 2018.

David R. Koos, who serves as Chairman and Chief Executive Officer of Zander also serves as Chairman and Chief Executive Officer of Entest. Zander is under common control with Entest. 

XML

Income Taxes

12 Months Ended

Aug. 31, 2018

Income Tax Disclosure [Abstract]

Income Taxes

NOTE 7.  INCOME TAXES

As of August 31, 2018
Deferred tax assets:
Net operating tax carry forwards	$	2,156,652
Other		-0-
Gross deferred tax assets		2,156,652
Valuation allowance		(2,156,652	)
Net deferred tax assets	$	-0-

As of  August 31, 2018  the Company has a Deferred Tax Asset of $2,156,652 completely attributable to net operating loss carry forwards of approximately $ 10,269,773(which expire 20 years from the date the loss was incurred) consisting of:

(a) $ 13,647 of Net Operating Loss carry forwards acquired in the reverse acquisition of Entest BioMedical, Inc., a California corporation, and

(b) $ 10,256,126 of Net Operating Loss carry forwards attributable to Entest BioMedical, Inc.

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. In addition, the reverse acquisition in which Entest BioMedical, Inc. was involved in 2009 has resulted in a change of control.  Internal Revenue Code Sec 382 limits the amount of income that may be offset by net operating loss (NOL) carryovers after an ownership change. As a result, the Company has recorded a valuation allowance reducing all deferred tax assets to $ -0-.

Income tax is calculated at the 21% Federal Corporate Rate.

XML

Acquisition of Entest CA

12 Months Ended

Aug. 31, 2018

Business Combinations [Abstract]

Acquisition of Entest CA

NOTE 8.  ACQUISITION OF ENTEST CA

On July 10, 2009 the Company acquired 100% of Entest CA, a California corporation and wholly owned subsidiary of the Company, from BMSN for consideration consisting of (a) the issuance to BMSN of 10,000,000 newly issued common shares of Entest and (b) the return by Mr. Rick Plote of 10,000,000 shares of Entest’s common stock previously issued to him by Entest for cancellation.

XML

Acquisition of the Assets of Pet Pointers, Inc.

12 Months Ended

Aug. 31, 2018

Accounting Policies [Abstract]

Acquisition of the Assets of Pet Pointers, Inc.

NOTE 9.  ACQUISITION OF THE ASSETS OF PET POINTERS, INC.

On January 4, 2011 Entest CA acquired from Pet Pointers, Inc., a California corporation doing business as McDonald Animal Hospital (“Seller”), and Dr. Gregory McDonald DVM (“McDonald”) all the goodwill from McDonald and assets of Seller except cash and accounts receivables used in connection with the operation of a veterinary medical clinic located at 225 S. Milpas Street, Santa Barbara, CA 93103 (the "Business").

Consideration for the acquisition consisted of:

   I. $70,000 in cash

   II. $210,000 of the Company’s common shares valued at the closing price per share as of January 4, 2011

   III. Payment of no more than $78,000 to a creditor of the Seller to be paid in monthly installments of $1,500 per month

   IV. Payment of no more than $25,000 to additional creditors of the Seller to be paid in monthly installments of $825 per month

   V. Payment of $50,000 to McDonald on the first business day of the fourth month following the closing of the acquisition (“Closing”).

XML

Disposition of the Assets of Pet Pointers, Inc.

12 Months Ended

Aug. 31, 2018

Business Combinations [Abstract]

Disposition of the Assets of Pet Pointers, Inc.

NOTE 10. DISPOSITION OF THE ASSETS OF PET POINTERS, INC.

On November 28, 2012 the “Company executed an agreement (“Agreement”) with Gregory McDonald ("McDonald"), Pet Pointers, Inc. ("Pet Pointer") whereby Mc Donald and Pet Pointer would acquire from the Company all assets (with the exception of cash and accounts receivable) utilized by the Company in the operation of the McDonald Animal Hospital, a full service veterinary clinic owned and operated by the Company and located in Santa Barbara, California (“McDonald Asset Sale”).

On October 10, 2012 a Complaint (“Complaint”) was filed in the Superior Court of the State of California against the Company and David Koos by McDonald, a former employee of the Company, alleging breach of contract and breach of the covenant of good faith and dealing in connection with the assumption of lease obligations by the Company in connection with the acquisition of the assets of Pet Pointers, Inc breach of contract and breach of the covenant of good faith and dealing in connection with an employment agreement enters into with McDonald inc connection with the Acquisition, breach of contract in connection with the Acquisition purchase agreement, breach of the covenant of good faith and dealing in connection with the Acquisition purchase agreement, implied indemnity in connection to amounts owed by McDonald to Anthony and Judi Marinelli, the Internal Revenue Service, and the California Franchise Tax Board, intentional misrepresentation, negligent misrepresentation , failure to pay wages and violations of Sections 2802, 203, and 2806 of the California Labor Code. The Complaint sought judgment for nominal damages, actual damages, compensatory damages, lost wages, compensation, expenses wage benefits and penalties pursuant to California Labor Code Sections 203 et al, 2802 and 2806, indemnification, accrued interest, punitive damages, costs of suit and attorney’s fees.

As consideration to the Company for the assets acquired, McDonald and Pet Pointers provided to the Company a General release whereby McDonald and Pet Pointer waive, release and discharge the Company and their respective assignees, officers, directors, shareholders, boards, owners, employees, attorneys, agents, trustors, trustees, beneficiaries, heirs, successors, and representatives from all known and unknown claims, demands, causes of action, attorney's fees, costs, or expenses including: 

(1) All claims relating to the Complaint.

(2) Those owed by McDonald to Anthony and Judi Marinelli which the Company became obligated to pay on McDonald’s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.

(3) Those amounts owed by McDonald to the Internal Revenue Service which the Company became obligated to pay on McDonald’s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.

(4) Those amounts owed by McDonald to the California Franchise Tax Board which the Company became obligated to pay on McDonald’s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.

Assets disposed of pursuant to the Agreement include approximately $4,840 of Property Plant and Equipment net of accumulated depreciation as well as all inventory held at the McDonald Animal Hospital.

Assets disposed of pursuant to the Agreement also include 

(i) Essentially all intellectual property, including computer software, utilized in connection with the operation of the McDonald Animal Hospital

(ii) All telephone numbers, fax numbers, service marks, trademarks, trade names, fictitious business names, websites, business email addresses, vendor lists, promotional materials, vendor records and any and all business records including, but not limited to, such items stored in computer memories, microfiche, paper record or by any other means relevant to the operation of the McDonald Animal Hospital.

(iii) All customer lists, customer contacts, and any and all customer records that are related to the McDonald Animal Hospital.

As a result of the agreement, the Company recorded a non-cash pre-tax charge for the impairment of goodwill recorded in connection with the acquisition of the McDonald Animal Hospital of approximately $405,000 for the quarter ended November 30, 2012.

Pursuant to the Agreement, the Company is obligated to make payment of $13,000 within five days of the Closing of the Agreement as such term is defined in the Agreement.

Pursuant to the Agreement, the Company agrees to waive, release and discharge McDonald and Pet Pointer from all known and unknown claims, demands, causes of action, attorney's fees, costs, or expenses.

XML

Deconsolidation of Zander Therapeutics, Inc.

12 Months Ended

Aug. 31, 2018

Notes to Financial Statements

Deconsolidation of Zander Therapeutics, Inc.

NOTE 11. DECONSOLIDATION OF ZANDER THERAPEUTICS, INC.

On May 5, 2018, The Company declared the distribution on a pro rata basis as a dividend in kind of 3,000,000 of the common shares of Zander Therapeutics, Inc., par value $0.0001, currently owned by Entest Group, Inc. to:

(a) Holders of record of the outstanding common shares of the Company as of the record date, which is May 30, 2018.

(b) Holders of record of the shares of any outstanding series of the preferred shares of the Company as of the record date, which is May 30, 2018.

Shareholders of the Company shall receive one (1) common share of Zander Therapeutics, Inc. for each 17 common and/or preferred shares of the Company held as of the record date. The distribution of the 3,000,000 common shares of Zander Therapeutics, Inc. to the common and preferred shareholders of the Company occurred on June 11, 2018 ("Distribution Date").

As a result of the payment of the abovementioned property dividend, the Company’s percentage of ownership of Zander fell below 50% resulting in the deconsolidation of Zander as of the Distribution Date. As of the Distribution Date all assets and liabilities attributable to Zander were derecognized by the Company. The Company recognized a $10,034gain as a result of the deconsolidation. The Property dividend may be deemed to have occurred with a related party as the recipients were shareholders of Entest, including the Chairman and Chief Executive Officer of Entest and Regen Biopharma, Inc. which is a company under common control with Entest.

The Company’s remaining share of Zander , which consists of 5,000,000 shares of Zander’s Series M Preferred Stock (“Zander M Stock”) is accounted for under the Equity Method as of the Distribution Date. The Zander M Stock is carried a Fair Value and the carrying value is increased by the Company’s proportionate share of earnings of Zander and decreased by cash dividends paid by Zander as well as the Company’s proportionate share of losses of Zander up to the carrying value . As of August 31, 2018 the carrying value of the Zander M Stock has been decreased by the Company’s proportionate share of the losses of Zander and is 0. As of August 31, 2018 Entest beneficially owns 34.82% of the share equity of Zander.

5 million shares of Zander Series M Preferred Stock received by the Company on June 15, 2017 in consideration of services rendered has been valued by the Company as of the deconsolidation date utilizing the following inputs:

Fair Value of Intellectual Property	1,030
prepaid Expenses	168,000
Accounts Payable	454,493
Due from Entest	7,357
Accrued Expenses	2,148
Enterprise Value	633,028
Less: Total Debt	(463,998	)
Enterprise Value available to Shareholders	169,030
Per Share	0.012286

The Chairman and Chief Executive Officer of the Company and Zander is David R. Koos. Zander may be considered a related party of the Company.

SUMMARY INFORMATION FOR ZANDER THERAPEUTICS ,INC. FOR THE FISCAL YEAR ENDED AUGUST 31, 2018 

Revenue	0
Operating Loss	(2,801,376	)
Net Loss	(2,780,288	)
Portion of Net Loss attributable to Entest	(968,188	)

XML

Commitments and Contingencies

12 Months Ended

Aug. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

NOTE 12. COMMITMENTS AND CONTINGENCIES

On November 1, 2011, the Company entered into an agreement to lease approximately 2,320 square feet of office space beginning December 1, 2011 for a period of five years.

Rent to be charged to the Company pursuant to the lease is as follows:

$2,996 per month for the period beginning December 1, 2011 and ending November 30, 2012

$3,116 per month for the period beginning December 1, 2012 and ending November 30, 2013

$3,241 per month for the period beginning December 1, 2013 and ending November 30, 2014

$3,371 per month for the period beginning December 1, 2014 and ending November 30, 2015

$3,506 per month for the period beginning December 1, 2015 and ending November 30, 2016

On November 27, 2016 the lease was extended until November 30, 2021

Rent to be charged to the Company pursuant to the extension is as follows:

 $2,996 per month for the period beginning December 1, 2016 and ending November 30, 2017

$3,116 per month for the period beginning December 1, 2017 and ending November 30, 2018

$3,241 per month for the period beginning December 1, 2018 and ending November 30, 2019

$3,371 per month for the period beginning December 1, 2019 and ending November 30, 2020

$3,506 per month for the period beginning December 1, 2020 and ending November 30, 2021

This property is utilized as office space. The Company believes that the foregoing property is adequate to meet its current needs.

XML

Investment Securities

12 Months Ended

Aug. 31, 2018

Accounting Policies [Abstract]

Investment Securities

NOTE 13. INVESTMENT SECURITIES

On February 28, 2017 the Company purchased 3,500,000 of the Series A Preferred shares of Regen Biopharma, Inc.for consideration consisting of $5,000 and 500,000 shares of the Company’s Series B Preferred stock.

The Series A Preferred shares of Regen Biopharma, Inc. described above constitute the Company’s sole investment securities as of August 31, 2017. The Company had no investment securities as of August 31, 2018

As of August 31, 2017:

	3,500,000		Series A Preferred shares of Regen Biopharma, Inc
	Basis		Fair Value	Total Unrealized Gains in Other Comprehensive Income	Net Unrealized Gain or (Loss) realized during the quarter  ended August 31, 2017
$	$5,000	$	$190,050	$185,050	$53,550

XML

Stockholders Equity

12 Months Ended

Aug. 31, 2018

Equity [Abstract]

Stockholders Equity

NOTE 14. STOCKHOLDERS EQUITY

The stockholders' equity section of the Company contains the following classes of capital stock as of August 31, 2018:

Common Stock:

$0.0001 par value, 500,000,000 shares authorized and 49,170,472 shares issued and outstanding as of August 31, 2018.

Preferred Stock:

$0.0001 par value 5,000,000 shares authorized of which:

(a)	100,000 are authorized as Series AA Preferred Stock of which 634 shares are issued and outstanding  as of  August 31, 2018  and
(b)	4,400,000 are authorized as Series B Preferred Stock of which 728,073 shares are issued and outstanding as of August 31, 2018 and
(c)	300,000  are authorized as Series AAA Preferred Stock of which 534 shares are issued and outstanding  as of  August 31, 2018.

Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series B Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.10 per share of Series B Preferred Stock (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series B Preferred Stock held by them.

If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series B Preferred Stock, then the entire net assets of the Company shall be distributed among the holders of the Series B Preferred Stock, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions August be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board..

Non Voting Convertible Preferred Stock having a $1.00 par value:

3,000,000 shares authorized of which 1,001,533 shares are issued and outstanding as of August 31 2018 .

Non Voting Convertible Preferred Stock shall convert at the option of the holder into shares of the corporation’s common stock at a conversion price equal to the greater of $0.01 per share or seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert.

“CLOSING PRICE" shall mean the closing bid price for the corporation’s common stock on the Principal Market on a Trading Day as reported by Bloomberg Finance L.P.

“PRINCIPAL MARKET" shall mean the principal trading exchange or market for the corporation’s common stock.

“TRADING DAY” shall mean a day on which the Principal Market shall be open for business.

XML

Stock Transactions

12 Months Ended

Aug. 31, 2018

Notes to Financial Statements

Stock Transactions

NOTE 15. STOCK TRANSACTIONS

On September 8, 2017 the Company issued 2,500,000 Common Shares in connection with a conversion of 25,000 Non Voting Convertible Preferred Shares.

XML

Subsequent Events

12 Months Ended

Aug. 31, 2018

Subsequent Events [Abstract]

Subsequent Events

NOTE 16. SUBSEQUENT EVENTS

On October 2, 2018 Entest Group, Inc. (the “Company”) amended Article 4 of the Company’s Articles of Incorporation to be and read as follows:

4. Authorized Shares:

The aggregate number of shares, which the corporation shall have authority to issue, shall consist of 500,000,000 shares of Common Stock having a $.0001 par value, and 5,000,000 shares of Preferred Stock having a $.0001 par value and 3,000,000 shares of Non Voting Convertible Preferred Stock having a $1.00 par value.

Non Voting Convertible Preferred Stock shall convert at the option of the holder into shares of the corporation’s common stock at a conversion price equal to the greater of (i) $0.001 per share or (ii) seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert.

“CLOSING PRICE" shall mean the closing bid price for the corporation’s common stock on the Principal Market on a Trading Day as reported by Bloomberg Finance L.P.

“PRINCIPAL MARKET" shall mean the principal trading exchange or market for the corporation’s common stock.

“TRADING DAY” shall mean a day on which the Principal Market shall be open for business.

The Common and/or Preferred Stock of the Company may be issued from time to time without prior approval by the stockholders. The Common and/or Preferred Stock may be issued for such consideration as may be fixed from time to time by the Board of Directors- The Board of Directors may issue such share of Common and/or Preferred Stock in one or more series, with such voting powers, designations, preferences and rights or qualifications, limitations or restrictions thereof as shall be stated in the resolution or resolutions.”

On November 16, 2018 Entest terminated its lease on office space. The property has been assumed by BST Partners which is permitting the Company to utilize the space free of charge on a week to week basis.

BST Partners is controlled by David Koos, the Company’s Chairman and Chief Executive Officer.

On November 16, 2018 Zander Therapeutics Inc. and the Company agreed to terminate Zander’s sublease with the Company ( See Note 6) effective the rental period commencing November, 2018.

On November 16, 2018 Regen Biopharma Inc. and the Company agreed to terminate Regen’s sublease with the Company ( See Note 6) effective the rental period commencing November, 2018.

David R. Koos serves as Chairman and Chief Executive Officer of the Company, Zander Therapeutics, Inc. and Regen Biopharma Inc.

On November 16, 2018:

Entest Group, Inc. and David R. Koos agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to Koos by Entest from the beginning of time to November 30, 2018 by transferring to Koos 3,000,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company

Entest Group, Inc. and Blackbriar Partners (“BP) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BP by Entest from the beginning of time to November 30, 2018 by transferring to BP 20,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. BP is controlled by David Koos the Company’s sole officer and director.

Entest Group, Inc. and the Sherman Family Trust (“SFT”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to SFT by Entest from the beginning of time to November 30, 2018 by transferring to SFT 612,500 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

Entest Group, Inc. and Dunhill Ross Partners (“DR”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to DR by Entest from the beginning of time to November 30, 2018 by transferring to DR 12,500 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

Entest Group, Inc. and the Bio Technology Partners Business Trust (“BPBT”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BPBT by Entest from the beginning of time to November 30, 2018 by transferring to BPBT 412,500 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

Entest Group, Inc. and the Bio Matrix Scientific Group, Inc. (“BMSN”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BMSN by Entest from the beginning of time to November 30, 2018 by transferring to BMSN 5,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. David R. Koos serves as Chairman and Chief Executive Officer of the Company and BMSN.

Entest Group, Inc. and Bostonia Partners (“BSP”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BSP by Entest from the beginning of time to November 30, 2018 by transferring to BSP 212,500 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

Entest Group, Inc. and Regen Biopharma, Inc. (“RGBP”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to RGBP by Entest from the beginning of time to November 30, 2018 by transferring to RGBP 250,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

Entest Group, Inc. and Regen Biopharma, Inc. (“RGBP”) agreed to satisfy any and all rent prepaid by RGBP to Entest from the beginning of time to November 30, 2018 by transferring to RGBP 475,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

David R. Koos serves as Chairman and Chief Executive Officer of the Company and RGBP.

XML

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Aug. 31, 2018

Accounting Policies [Abstract]

Basis of Accounting

A. BASIS OF ACCOUNTING

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted an August 31 fiscal year-end.   The Company recognizes revenue from services and product sales when the following four revenue recognition criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the selling price is fixed or determinable, and collectability is reasonably assured.

Principles of Consolidation

B. PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the accounts of Entest CA, the Company’s wholly owned subsidiary. These financial statement also include the accounts of Zander up to June 10, 2018. Significant inter-company transactions have been eliminated.

Use of Estimates

C. USE OF ESTIMATES

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash Equivalents

D. CASH EQUIVALENTS

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

Property and Equipment

E. PROPERTY AND EQUIPMENT

As of August 31, 2018 Property and Equipment consists of $0

Fair Value of Financial Instruments

F. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

Level 1:  Quoted prices in active markets for identical assets or liabilities

Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company’s financial instruments as of August 31, 2018 consisted of $ 19,601 of Notes Payable and $8,000 due to TheraCyte, Inc.. The fair value of all of the Company’s financial instruments as of August 31, 2018 were valued according to the Level 3 input. The carrying amount of the financial instruments is equal to the fair value as determined by the Company.

The Company has determined that there are no Level 1 or Level 2 inputs for determining the fair value of the Company’s financial instruments. Fair value was determined by the Company utilizing its own assumptions and estimation. There were no transfers between levels for the period presented.

Income Taxes

G. INCOME TAXES

The Company accounts for income taxes using the liability method prescribed by ASC 740, “ Income Taxes. ” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company applied the provisions of ASC 740-10-50, “Accounting for Uncertainty in Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of August 31, 2018 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

Basic Earnings (Loss) Per Share

H.  BASIC EARNINGS (LOSS) PER SHARE

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. All convertible debt has an anti-dilutive effect on the EPS, therefore Diluted earnings per share are the same as basic earnings per share.

XML

Notes Payable (Tables)

12 Months Ended

Aug. 31, 2018

Debt Disclosure [Abstract]

Notes Payable

David Koos (See Note 6)	$	2,600
Dunhill Ross Partners, Inc.	$	850
Blackbriar Partners (See Note 6)		11,600
Regen Biopharma, Inc (See Note 6)		4,551
Total	$	19,601

XML

Income Taxes (Tables)

12 Months Ended

Aug. 31, 2018

Income Tax Disclosure [Abstract]

Deferred Tax Assets

As of August 31, 2018
Deferred tax assets:
Net operating tax carry forwards	$	2,156,652
Other		-0-
Gross deferred tax assets		2,156,652
Valuation allowance		(2,156,652	)
Net deferred tax assets	$	-0-

XML

Deconsolidation of Zander Therapeutics, Inc. (Tables)

12 Months Ended

Aug. 31, 2018

Notes to Financial Statements

Schedule of deconsolidation

Fair Value of Intellectual Property	1,030
prepaid Expenses	168,000
Accounts Payable	454,493
Due from Entest	7,357
Accrued Expenses	2,148
Enterprise Value	633,028
Less: Total Debt	(463,998	)
Enterprise Value available to Shareholders	169,030
Per Share	0.012286

Summary Information For Zander Therapeutics ,Inc

Revenue	0
Operating Loss	(2,801,376	)
Net Loss	(2,780,288	)
Portion of Net Loss attributable to Entest	(968,188	)

XML

Investment Securities (Tables)

12 Months Ended

Aug. 31, 2018

Accounting Policies [Abstract]

Comprehensive Income

	3,500,000		Series A Preferred shares of Regen Biopharma, Inc
	Basis		Fair Value	Total Unrealized Gains in Other Comprehensive Income	Net Unrealized Gain or (Loss) realized during the quarter  ended August 31, 2017
$	$5,000	$	$190,050	$185,050	$53,550

XML

Organization and Description of Business (Details Narrative)	Aug. 31, 2018	Jul. 10, 2010	Jul. 10, 2009
Acquisition of share capital of Company			100.00%
Zander [Member]
Acquisition of share capital of Company	34.82%
Entest CA
Acquisition of share capital of Company		100.00%

XML

Summary of Significant Accounting Policies (Details Narrative)	12 Months Ended
	Aug. 31, 2018 USD ($)
Accounting Policies [Abstract]
Property and Equipment	$ 0
Notes payable	19,601
Due to TheraCyte, Inc	$ 8,000
Valuation allowance	100.00%

XML

Going Concern (Details Narrative) - USD ($)	12 Months Ended		108 Months Ended
	Aug. 31, 2018	Aug. 31, 2017	Aug. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net (loss)	$ (1,477,484)	$ (559,418)	$ (10,256,126)

XML

Notes Payable - Notes Payable (Details)	Aug. 31, 2018 USD ($)
Notes Payable	$ 19,601
David Koos
Notes Payable	2,600
Dunhill Ross Partners, Inc.
Notes Payable	850
Blackbriar Partners
Notes Payable	11,600
Regen Biopharma, Inc [Member]
Notes Payable	$ 4,551

XML

Notes Payable (Details Narrative) - USD ($)	12 Months Ended
	Aug. 31, 2018	Aug. 31, 2017
Notes payable	$ 19,601	$ 13,501
Blackbriar Partners #2
Notes payable	$ 7,000
Interest rate per annum	10.00%
Note Due Date	Feb. 28, 2018
Blackbriar Partners #3
Notes payable	$ 3,000
Interest rate per annum	10.00%
Note Due Date	May 04, 2019
Blackbriar Partners #4
Notes payable	$ 600
Interest rate per annum	10.00%
Note Due Date	Aug. 20, 2019
Blackbriar Partners
Notes payable	$ 1,000
Interest rate per annum	10.00%
Note Due Date	Feb. 17, 2017
David Koos
Notes payable	$ 2,600
Interest rate per annum	15.00%
Regen Biopharma, Inc [Member]
Interest rate per annum	10.00%

XML

Related Party Transactions (Details Narrative) - USD ($)			1 Months Ended	12 Months Ended
	Jul. 03, 2018	Feb. 28, 2017	Jun. 15, 2017	Aug. 31, 2018	Aug. 31, 2017
Monthly rent revenue				$ 5,000
Preferred stock purchased		3,500,000
Cash consideration for purchase of Preferred Stock		$ 5,000
Preferred Stock Issued				0	0
Regen BioPharma Inc.
Amount due				$ 4,551
Interest rate per annum				10.00%
Blackbriar Partners #4
Amount due				$ 600
Interest rate per annum				10.00%
Note Due Date				Aug. 20, 2019
Blackbriar Partners #3
Amount due				$ 3,000
Interest rate per annum				10.00%
Note Due Date				May 04, 2019
Blackbriar Partners #2
Amount due				$ 7,000
Interest rate per annum				10.00%
Note Due Date				Feb. 28, 2018
Blackbriar Partners
Amount due				$ 1,000
Interest rate per annum				10.00%
Note Due Date				Feb. 17, 2017
David Koos
Amount due				$ 2,600
Interest rate per annum				15.00%
Regen Biopharma, Inc [Member]
Interest rate per annum				10.00%
Zander M Stock [Member]
Stock issued for consideration, Shares			5,000,000
NonVoting [Member]
Preferred Stock Issued				1,001,533	1,026,533
Series B
Preferred Stock Issued		500,000		728,009	728,009
Series AAA
Preferred Stock Issued				534	534
Series AA
Preferred Stock Issued				667	667
Zander [Member]
Stock issued for consideration, Shares	3,500,000
Stock issued for consideration, Value	$ 35,000
Monthly Sublease income	$ 6,000

XML

Income Taxes (Details)	Aug. 31, 2018 USD ($)
Deferred tax assets:
Net operating tax carry forwards	$ 2,156,652
Other	0
Gross deferred tax assets	2,156,652
Valuation allowance	(2,156,652)
Net deferred tax assets	$ 0

XML

Income Taxes (Details Narrative)	12 Months Ended
	Aug. 31, 2018 USD ($)
Income Tax Disclosure [Abstract]
Deferred tax asset	$ 2,156,652
Net operating loss carry forwards	10,269,773
Net operating loss carry forwards acquired in the reverse acquisition of Entest BioMedical, Inc.	13,647
Net operating loss carry forwards attributable to Entest BioMedical, Inc.	10,256,126
Deferred tax assets, net valuation allowance	$ 0
Federal Corporate Rate income tax	21.00%

XML

Acquisition of Entest CA (Details Narrative)	Jul. 10, 2009 shares
Business Combinations [Abstract]
Acquisition of Entest CA	100.00%
Newly issued common shares of Entest	10,000,000
Cancellation of shares of common stock	10,000,000

XML

Acquisition of the Assets of Pet Pointers, Inc. (Details Narrative)	Jan. 04, 2011 USD ($)
Accounting Policies [Abstract]
Acquisition of cash	$ 70,000
Acquisition of common shares	210,000
Maximum payment to creditor	78,000
Monthly installments to creditor	1,500
Maximum payment to additional creditors	25,000
Monthly installments to additional creditors	825
Monthly payment to McDonald	$ 50,000

XML

Disposition of the Assets of Pet Pointers, Inc. (Details Narrative) - USD ($)	2 Months Ended	3 Months Ended
	Nov. 28, 2012	Nov. 30, 2012
Business Combinations [Abstract]
Asset disposal, property plant and equipment	$ 4,840
Impairment of goodwill		$ 405,000
Obligated payment, Closing of agreement		$ 13,000

XML

Deconsolidation of Zander Therapeutics, Inc. (Details) - USD ($)	Aug. 31, 2018	Aug. 31, 2017
Prepaid Expenses	$ 8,000	$ 58,652
Accounts Payable	28,447	28,446
Accrued Expenses	181,904	$ 269,398
Zander [Member]
Fair Value of Intellectual Property	1,030
Prepaid Expenses	168,000
Accounts Payable	454,493
Due from Entest	7,357
Accrued Expenses	2,148
Enterprise Value	633,028
Less: Total Debt	(463,998)
Enterprise Value available to Shareholders	$ 169,030
Per Share	$ 0.012286

XML

Deconsolidation of Zander Therapeutics, Inc. (Details 1) - USD ($)	12 Months Ended		108 Months Ended
	Aug. 31, 2018	Aug. 31, 2017	Aug. 31, 2018
Revenue	$ 0	$ 0
Operating Loss	(1,520,899)	(651,879)
Net Loss	(1,477,484)	(664,792)
Portion of Net Loss attributable to Entest	(1,477,484)	$ (559,418)	$ (10,256,126)
Zander [Member]
Revenue	0
Operating Loss	(2,801,376)
Net Loss	(2,780,288)
Portion of Net Loss attributable to Entest	$ (968,188)

XML

Deconsolidation of Zander Therapeutics, Inc. (Details Narrative) - USD ($)			1 Months Ended	12 Months Ended
	Jul. 03, 2018	May 05, 2018	Jun. 15, 2017	Aug. 31, 2018	Aug. 31, 2017
Common shares par value				$ 0.0001	$ 0.0001
Gain on deconsolidation				$ 10,034	$ 0
Zander M Stock [Member]
Equity Method stock remaining		5,000,000
Decrease in carrying value				$ 0
Stock issued for consideration, Shares			5,000,000
Zander [Member]
Dividend in kind		3,000,000
Common shares par value		$ 0.0001
Distribution Date		Jun. 11, 2018
Gain on deconsolidation		$ 10,034
Ownership Percentage				34.82%
Stock issued for consideration, Shares	3,500,000

XML

Commitments and Contingencies (Details Narrative) - USD ($)	12 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Nov. 30, 2019	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2014	Nov. 30, 2013	Nov. 30, 2012
Commitments and Contingencies Disclosure [Abstract]
Office monthly lease payments	$ 3,506	$ 3,371	$ 3,241	$ 3,116	$ 2,996	$ 3,506	$ 3,371	$ 3,241	$ 3,116	$ 2,996

XML

Investment Securities (Details) - USD ($)	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2018
Accounting Policies [Abstract]
Investment Securities, Basis	$ 5,000
Investment Securities, Fair Value	190,050	$ 0
Investment Securities, Total Unrealized Losses	185,050
Investment Securities, Net Unrealized Loss during the quarter	$ 53,550

XML

Investment Securities (Details Narrative) - USD ($)	Feb. 28, 2017	Aug. 31, 2018	Aug. 31, 2017
Preferred stock purchased	3,500,000
Cash consideration for purchase of Preferred Stock	$ 5,000
Preferred Stock Issued		0	0
NonVoting [Member]
Preferred Stock Issued		1,001,533	1,026,533
Series B
Preferred Stock Issued	500,000	728,009	728,009
Series AAA
Preferred Stock Issued		534	534
Series AA
Preferred Stock Issued		667	667

XML

Stockholders Equity (Details Narrative) - $ / shares	12 Months Ended
	Aug. 31, 2018	Aug. 31, 2017	Feb. 28, 2017
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	49,170,472	46,670,472
Common stock, shares outstanding	49,170,472	46,670,472
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	4,400,000	4,400,000
Preferred stock, shares issued	728,009	728,009	500,000
Preferred stock, shares outstanding	728,009	728,009
Liquidation terms	Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series B Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.10 per share of Series B Preferred Stock (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series B Preferred Stock held by them. If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series B Preferred Stock, then the entire net assets of the Company shall be distributed among the holders of the Series B Preferred Stock, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions August be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board.
NonVoting [Member]
Preferred stock, par value	$ 1.00	$ 1.00
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	1,001,533	1,026,533
Preferred stock, shares outstanding	1,001,533	1,026,533
Liquidation terms	Non Voting Convertible Preferred Stock shall convert at the option of the holder into shares of the corporation’s common stock at a conversion price equal to the greater of $0.01 per share or seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert.
Series AA
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	100,000	100,000
Preferred stock, shares issued	667	667
Preferred stock, shares outstanding	667	667
Series AAA
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	300,000	300,000
Preferred stock, shares issued	534	534
Preferred stock, shares outstanding	534	534

XML

Stock Transactions (Details Narrative)	Sep. 08, 2018 shares
NonVoting [Member]
Preferred Shares Redeemed	25,000
Common Stock
Stock issued upon conversion	2,500,000

XML

Subsequent Events (Details Narrative) - $ / shares		1 Months Ended	12 Months Ended
	Oct. 02, 2018	Nov. 16, 2018	Aug. 31, 2018	May 05, 2018	Aug. 31, 2017	Feb. 28, 2017
Common stock, par value			$ 0.0001		$ 0.0001
Common stock, shares authorized			500,000,000		500,000,000
Preferred stock, par value			$ 0.0001		$ 0.0001
Preferred stock, shares authorized			5,000,000		5,000,000
Preferred stock, shares issued			0		0
Preferred stock, shares outstanding			0		0
NonVoting [Member]
Preferred stock, par value			$ 1.00		$ 1.00
Preferred stock, shares authorized			3,000,000		3,000,000
Preferred stock, shares issued			1,001,533		1,026,533
Preferred stock, shares outstanding			1,001,533		1,026,533
Liquidation terms			Non Voting Convertible Preferred Stock shall convert at the option of the holder into shares of the corporation’s common stock at a conversion price equal to the greater of $0.01 per share or seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert.
NonVoting [Member] | Subsequent Event [Member]
Preferred stock, par value	$ 1.00
Preferred stock, shares authorized	3,000,000
Liquidation terms	Non Voting Convertible Preferred Stock shall convert at the option of the holder into shares of the corporation’s common stock at a conversion price equal to the greater of (i) $0.001 per share or (ii) seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert.
Series B
Preferred stock, par value			$ 0.0001		$ 0.0001
Preferred stock, shares authorized			4,400,000		4,400,000
Preferred stock, shares issued			728,009		728,009	500,000
Preferred stock, shares outstanding			728,009		728,009
Liquidation terms			Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series B Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.10 per share of Series B Preferred Stock (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series B Preferred Stock held by them. If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series B Preferred Stock, then the entire net assets of the Company shall be distributed among the holders of the Series B Preferred Stock, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions August be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board.
Preferred Stock [Member] | Subsequent Event [Member]
Preferred stock, par value	$ 0.0001
Preferred stock, shares authorized	5,000,000
Common Stock | Subsequent Event [Member]
Common stock, par value	$ 0.0001
Common stock, shares authorized	500,000,000
Series AA
Preferred stock, par value			$ 0.0001		$ 0.0001
Preferred stock, shares authorized			100,000		100,000
Preferred stock, shares issued			667		667
Preferred stock, shares outstanding			667		667
Series AAA
Preferred stock, par value			$ 0.0001		$ 0.0001
Preferred stock, shares authorized			300,000		300,000
Preferred stock, shares issued			534		534
Preferred stock, shares outstanding			534		534
Regen Biopharma, Inc [Member] | Zander M Stock [Member] | Subsequent Event [Member]
Number of shares issued to satisfy of accrued interest		250,000
Number of shares issued to satisfy of prepaid rent		475,000
Bostonia Partners [Member] | Zander M Stock [Member] | Subsequent Event [Member]
Number of shares issued to satisfy of accrued interest		212,500
David Koos [Member] | Zander M Stock [Member] | Subsequent Event [Member]
Number of shares issued to satisfy of accrued interest		3,000,000
Blackbriar Partners | Zander M Stock [Member] | Subsequent Event [Member]
Number of shares issued to satisfy of accrued interest		20,000
Sherman Family Trust | Zander M Stock [Member] | Subsequent Event [Member]
Number of shares issued to satisfy of accrued interest		612,500
Dunhill Ross Partners, Inc. | Zander M Stock [Member] | Subsequent Event [Member]
Number of shares issued to satisfy of accrued interest		12,500
Bio Technology Partners Business Trust [Member] | Zander M Stock [Member] | Subsequent Event [Member]
Number of shares issued to satisfy of accrued interest		412,500
Bio Matrix Scientific Group [Member] | Zander M Stock [Member] | Subsequent Event [Member]
Number of shares issued to satisfy of accrued interest		5,000
Zander [Member]
Common stock, par value				$ 0.0001